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The survival rate for patients with metastatic vs. localized cancer is 
dramatically reduced. Most cancer-related deaths are associated with the formation of 
secondary tumors. In order to form a secondary tumor, cancer cells must detach from 
the primary tumor, using a complex series of steps change the surrounding tissue 
making its way to the circulatory system, survive within the circulation and evade the 
immune system, and leave the circulatory system at a distal site to form a secondary 
tumor. While circulating, cancer cells interact with the endothelial lining of the 
vasculature via a series of adhesive interactions that facilitate tethering mediated via 
transient bond formation with the selectin group of glycoproteins. This ultimately 
leads to firm adhesion of cancer cells to vessels in the initial steps of metastasis.  
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), 
identified based on its homology to the TNF superfamily, holds promise as a tumor-
specific cancer therapeutic agent. Unlike other TNF family members, TRAIL specifically 
induces a death signal in transformed cells while sparing non-cancerous cells via a 
caspase-dependent pathway. In the present work, we exploit this phenomenon to deliver a 
receptor-mediated apoptosis signal to cancer cells under flow conditions. 
 My studies show that cancer cells exhibit shear-dependent rolling behavior over a 
selectin-coated microcapillary flow chamber and that the density of the selectin molecule, 
along with the shear force imposed by the flowing fluid on the cancer cell play an 
important role in regulating the rolling velocity. Further, I have demonstrated that 
flowing cancer cells through a microtube functionalized with TRAIL and E-selectin is 
capable of killing the captured cancer cells. This killing is time-dependent and is more 
efficient compared to static conditions with immobilized TRAIL and E-selectin. The 
functionalized microtubes do not kill healthy blood and bone marrow cells neither do 
they activate !2 integrin present on leukocytes.  
Studies suggest that many cancer cells that are resistant to TRAIL can be 
sensitized by chemotherapy and radiation. To this extent, the microtube device was tested 
for use as adjuvant therapy. When pre-treating cells with sublethal doses of 
chemotherapeutic agent, a super-additive (greater than the sum of kill by individual 
agent) increase in kill rate was seen. This represents the first demonstration of a novel 
biomimetic method to capture metastatic cells from circulation and deliver an apoptotic 
signal, thereby reducing the metastatic load with a hope to improve patient survival. 
Using a different approach, nanoscale lipid particles decorated with two proteins 
are developed that would bind circulating cancer cells and kill them. Results show that 
the lipid nanoparticles bind to cells under conditions of uniform shear with high 
efficiency and kill over 50% of cells in 2 hours. When cancer cells were spiked in blood, 
a kill of over 90% was seen when compared to control lipid nanoparticles.   
Before these modalities become therapies, further studies evaluating the efficacy 
in animal models are necessary. However, these results show promising possibilities in 
 killing metastatic cancer cells, thereby improving chances for patient survival.  
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Chapter 1 Background and Introduction 
 2 
Cancer is a disease of uncontrolled cell proliferation. The result of cancer, formation 
of a tumor, however is a complex process that occurs over a period of several years. 
Normal cells because of some aberration start to “evolve” into increasingly neoplastic 
phenotype through a process known as tumor progression. Eventually the tumor cells 
acquire enough mass to become hypoxic and as a result, angiogenesis occurs. When 
the tumor reaches a certain critical mass, it begins shedding cells that metastasize – 
travel to a distal location – and seed a secondary tumor. One of the ways cancer cells 
metastasize is via the circulatory system. While in circulation, the cancer cells interact 
with endothelial cells via selectins. Formation of secondary tumors leads to a drastic 
reduction in patient survival, making metastatic tumors a critical factor in the final 
outcome of the disease. 
1.1 Cancer Metastasis 
During the initial stages of tumor progression, the cancer cells multiply in an 
uncontrolled manner, the result of which, a tumor, may take several years to manifest. 
These tumors, depending on their location, may expand to a much larger size without 
any discomfort or impairment of bodily function. For example, tumors in cavities (e.g. 
peritoneal carcinoma) can grow to relatively large sizes without causing any 
discomfort while tumors in the brain are detected while relatively small as they start to 
impair function. The effect of the growing tumor mass exerts physical pressure on the 
surrounding tissue and may cause a change in the functioning of normal tissue. For 
example, tumors in the lung may obstruct airflow in the lungs. Eventually all tumors, 
irrespective of their location, start to impair normal bodily function.  
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Dealing with the primary tumor is relatively easy. Treating the primary tumor 
with chemotherapy or radiation often neutralizes the tumor. Alternatively, the tumor 
can be surgically removed. Most cancer-related deaths are a result of forming the 
secondary tumor because of metastasis. 
Metastasis of epithelial tumors is a complex, but well-defined process starting 
with  (1) a primary neoplastic lesion (2) followed by epithelial-mesenchymal transition 
or EMT and basement membrane breach, (3) invasion of surrounding tissue, (4) 
intravasation into blood vessels or lymphatic ducts, (5) transport to a distal location 
through vessels, extravasation from the blood vessel, (6) mesenchymal-epithelial 
transition or MET and (7) establishment of tumor microenvironment to eventually 
form the secondary tumor (Chambers 1999; Chambers et al. 1995; Chambers et al. 
2001; Coghlin and Murray 2010; Thiery 2002; Thiery 2003).  
Epithelial tissue is arranged in thin sheets. These sheets are in turn separated 
from the stroma by the basement membrane. In the case of cancer progression, cancer 
cells undergo a process known as EMT wherein epithelial cells acquire the properties 
of mesenchymal cells. EMT is characterized by the loss of polarization and adhesion 
molecules namely E-cadherin (Kalluri and Weinberg 2009; Klymkowsky and 
Savagner 2009; Micalizzi and Ford 2009; Zeisberg and Neilson 2009). This allows 
cells to move with relatively fewer restrictions. 
To reach the next stage in the metastatic cascade, the cells must acquire the 
ability to migrate. From studies of cell movement in two dimensions or within three 
dimensional gels and using advanced intravital microscopy, information has been 
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gathered on the forces generated by cells (Paszek et al. 2005) and movement of cells 
(Condeelis and Segall 2003; Friedl and Wolf 2003; Lauffenburger and Horwitz 1996). 
Cells start migrating by extending their cell membrane. This process is driven by actin 
polymerization and depolymerization. Cytoplasmic extensions of cells attach to the 
extracellular matrix via integrin- and focal adhesion kinase containing complexes. 
Cells move by contracts towards the leading edge while releasing adhesion molecules 
at the trailing edge (Paszek et al. 2005). Tumors may migrate either as single cell or 
collectively as clusters (Friedl and Wolf 2003). Several adhesion molecules and 
signaling molecules including integrins, CD44 (including variants) and 
Immunoglobulin-domain Cell Adhesion Molecules have been implicated in cell 
migration and tumor invasion (Alves et al. 2008; Cabodi et al. 2010; Cavallaro and 
Christofori 2004; Hanley et al. 2006; Konstantopoulos and Thomas 2009). Metastatic 
cells, in general, tend to be polarized to migrate towards blood vessels (Condeelis and 
Segall 2003).  
Intravasation starts with the directional migration of cancer cells towards blood 
vessels. Cancer cells extend their membrane and protrude through gaps in the 
endothelial junctions while clusters of cancer cells may enter through leaky lymph 
vessels (Carr et al. 1980; Cavallaro et al. 2001). Another mechanism involves the 
cancer cells replacing the endothelial cells by themselves, forming mosaics (Chang et 
al. 2000; Tremblay et al. 2008). (Butler and Gullino 1975). 
Once the cells enter the body’s expressways, they can travel to a distal location. 
While in circulation the cells must survive the hostile environment of the circulation. 
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Surviving high shear stresses, evading the natural immune system and avoiding lysis 
due to mechanical trapping, are essential for the cancer cell to survive the circulation 
(MacDonald et al. 2002). All these and other factors constitute metastatic 
inefficiencies. Two distinct mechanisms for interaction of cancer cells with the 
endothelium have been suggested. The first is mechanical trapping while the second is 
similar to that of leukocytes under an inflammatory response (Chambers 1999; 
Chambers et al. 1995; Chambers et al. 2001). As cancer cells travel the blood vessels 
eventually reaching capillary beds, cancer cells are trapped within the small vessels. 
Other blood cells being much smaller (leukocyte ~ 10 !m, cancer cell > 20 !m) and 
more deformable are able to pass through these small sized vessels. This phenomenon 
also explains why secondary tumors are usually seen in highly vascularized organs 
like the liver and the lungs. There is evidence that cancer cells interact with the 
endothelium in a manner similar to that of leukocytes under an inflammatory 
response(Krause and Turner 1999; Zaifert and Cohen 1993). Eventually the cells come 
to firm arrest and start to migrate out of the vessel (Woodward 2008) into the tissue 
where the reverse process takes place -  invasion, mesenchymal to epithelial transition 
(MET) and finally establishment of a new tumor. Figure 1.1 summarizes the process 
described above.  
Tumors tend to metastasize to specific organs. Several theories have been 
suggested to explain this observed phenomenon (Gassmann et al. 2004; Nicolson 
1988).  Paget introduced the “seed and soil” theory, wherein he compares the cancer 
cells to seeds that are dispersed by plants in all directions. Upon reaching the 
appropriate location or the “right soil” the seed would germinate (Paget 1889). Similar 
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observations were later made in mouse melanoma (Hart and Fidler 1980; Kats-Ugurlu 
et al. 2009). Other studies suggest that the blood flow patterns influence the spread of 
cancer to specific sites (Hart 2009; Kats-Ugurlu et al. 2009). One theory states that the 
location of the tumor has something to do with the location of metastasis (Coghlin and 
Murray 2010). For example, the proximity of breast tissue to the lungs causes breast 
cancer cells to metastasize to the lungs or the presence of the portal vein near the 
colon leads to colon cancer cells metastasize to the liver. Expression of chemokines 
that may attract cancer cells towards a particular tissue has also been suggested. 
Another theory proposed by Weinberg and co-workers proposed the formation of 
metastatic niches (Bernards and Weinberg 2002; Weinberg 2008). They postulated 
that the selection pressure within the microenvironment of the primary tumor does not 
favor a phenotypic change to a metastatic phenotype. Weinberg and co-workers 
suggest that the metastatic ability was acquired early on in the tumorigenesis process 
was proposed. They argued that cells that acquire the phenotype of metastasis would 
still be very rare as they may not necessarily have any proliferative advantage. Based 
on this hypothesis, researchers have proposed two additional models, the ‘early 
metastasis model’ and the ‘late metastasis model’ (Klein 2008). In the early metastasis 
model, some cancer cells leave the primary tumor early and change genetically. These 
cells may then start their own metastatic cascade. However, in the late metastasis 
model cells from the primary tumor escape at a much later stage and hence are similar 
to the primary tumor genetically.   
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1.2 Adhesion Molecule - Selectins 
Selectins are a family of transmembrane, carbohydrate-binding proteins. They 
are intercellular adhesion molecules and are responsible for reversible leukocyte 
adhesion to the endothelium (Ley and Gaehtgens 1991; McEver 1997). Selectins are 
type I membrane proteins. Three distinct members of selectins have been identified: L-, 
P- and E-selectin. All selectins share a similar structure, with a C-type lectin domain at 
the N-terminus followed by an epidermal growth factor (EGF) – like motif, 2 to 9 
consensus repeat units, a transmembrane domain and a cytoplasmic tail at the C-
terminus (Figure 1.2A). Selectin binding is calcium dependent. A calcium-binding site 
exists within the structure that converts the selectin into its active form (McEver 1997). 
Selectins have been directly or indirectly implicated in cancer extravasation (Borsig et 
al. 2002; Witz 2006). 
L-selectin is constitutively expressed on most leukocytes including neutrophils, 
monocytes, basophils, eosinophils and most T- and B-cells (Bird et al. 1997). It plays 
a role in leukocyte homing to peripheral lymph nodes and in adhesion of neutrophils 
to inflamed endothelium (McEver 1997). L-selectin has also been implicated in 
forming leukocyte aggregates and is involved in signaling in leukocytes (Lee and King 
2007). Interestingly, upon activation, L-selectin is cleaved from the surface, making 
the cell less adhesive (Lee et al. 2007). 
P-selectin is stored in the Weibel-Palade bodies in endothelial cells and in the 
!-granules of platelets. Upon stimulation by thrombin, histamine, fibrin, complement 
component C5b-9 or vascular permeability factor, P-selectin in the granules is 
distributed to the plasma membrane within minutes (Iwamura et al. 1997; Stone and 
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Wagner 1993). P-selectin plays a role in leukocyte extravasation at sites of vascular 
injury by mediating the rolling of neutrophils and monocytes on endothelial cells. In 
addition, it is responsible for the binding of platelets to these phagocytic cells 
(Iwamura et al. 1997; Pottratz et al. 1996; Stone and Wagner 1993). 
Upon activation of endothelial cells by TNF-! or bacterial endotoxins, E-
selectin is synthesized de novo in endothelial cells and then translocated to the surface 
(Iwamura et al. 1997; Ye et al. 1995). Similar to P-selectin, E-selectin mediates rolling 
of leukocytes and eventual transmigration to the site of inflammation (Dimitroff et al. 
2005; McEver 1997; Zarbock et al. 2007).  Peak levels of E-selectin expression are 
reached one to four hours after the initial signal (Ye et al. 1995). 
1.2.1 Mechanics of Selectin-Mediated Adhesion Under Flow 
As discussed in the previous section, selectins play an important role in 
recruiting leukocytes from the circulation. Looking at this process from a reaction 
standpoint between selectins and their ligands, relatively fast rates of bond formation 
are required to capture fast moving cells. The bonds formed should be capable of 
balancing the hydrodynamic forces and the torque experienced by the cell as a result 
of flow (Konstantopoulos et al. 1998). The fast rate of disassociation (roff,) coupled 
with the strength and the rate of bond formation (ron), allows cells to roll over the 
endothelial surface. If the interactions between selectins (S) and their ligands (L) are 
represented as a first-order reversible reaction with ron as the rate of forward reaction 
(formation of the selectin-selectin ligand bond) and roff as the rate of the reverse 
reaction (dissociation of selectin – selectin ligand bonds), then the rate equations may 
be represented as; 
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Where Cs, CL, CSL are the concentration of selectin, selectin-ligand and the selectin-
selectin ligand complex respectively, t is time and kon and koff are the rate constants for 
formation and disassociation of the form; 
!!"" ! !!!"#
!!!!
!!!
 
where, kB is the Boltzmann constant, T is temperature, Fb is the bond rupture force, xb 
is the reactive compliance and k0 is the unstressed rate constant (Orsello et al. 2001). 
Measuring kon is difficult as kon is dependent on local concentrations of 
reactants which change due to the diffusion of membrane bound proteins on the cell 
surface (Orsello et al. 2001). However, measuring koff is relatively easy. At low 
concentrations, we can assume the binding events are due to single bonds. By plotting 
ln Cs vs. t and measuring the intercept of the linear fit, it is possible to experimentally 
obtain the dissociation constant (Alon et al. 1997; Alon et al. 1995). Since the forward 
and reverse reactions are interdependent for reversible reactions, reactions with high 
koff can also be expected to have high kon (Alon et al. 1997; Puri et al. 1997). 
The rate of dissociation is directly proportional to roff for the selectin: selectin-
ligand complex (Alon et al. 1997) and consequently on koff , while ron or kon is a 
measure of cell recruitment (Konstantopoulos et al. 1998). During rolling, cells form 
new bonds while breaking the old bonds. Thus, rolling is a balance between the rates 
 
ron =
dCSCL
dt = konCSCL
 
roff = "
dCSL
dt = "koff CSL
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of dissociation and formation. Then, cell detachment depends on the ratio of roff to ron. 
Low roff:ron implies that there is high resistance to detachment (Puri et al. 1997). As 
can be seen from the rate equations, the rolling behavior is highly influenced by the 
density of selectin and selectin-ligands available to bind. Hence, cells with a higher 
number of functional ligands on their surface for a given surface density of selectins, 
the forward reaction (bond formation) is favored leading to higher ron and lower roff. 
The overall result is lower rolling velocities, more cell recruitment and more resistance 
to detachment.  
Force balance assays are typically used to calculate rolling velocities and 
rolling fluxes (Ley and Gaehtgens 1991). With an increase in selectin surface 
concentration, the rolling velocity will decrease and flux will approach a maximum 
until a point when most of the available ligands in the contact region of the cell are 
bound to selectin. The rolling flux can begin to decrease if the rolling velocity 
approaches zero since the cells are no longer considered to be rolling and, in fact, 
become firmly adherent. 
1.2.2 Selectins in Cancer 
Selectins have been implicated in cancer progression with therapies and 
strategies that involve inhibiting selectin-mediated adhesion (Fuster and Esko 2005; 
Yin et al. 2010). Studies with prostate cancer cells have been shown to roll on human 
bone derived endothelium (Dimitroff et al. 2004). Similar studies in flow chambers 
have shown the interaction of cancer cells with immobilized selectin (Burdick et al. 
2001; F. William Orr 2000; Iwamura et al. 1997; Klementsen and Jorgensen 1997; 
Pottratz et al. 1996; Ye et al. 1995; Zaifert and Cohen 1993). 
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Studies with animal models have shown that selectins are involved in the 
process of metastasis, in particular E-selectin. A substantial reduction in the 
occurrence of metastasis in mice was observed when sialyl lewis x (sLex) antibody or 
synthetic sLex were injected with cancer cells (Nakashio et al. 1997; Saiki et al. 1996). 
Sato and coworkers compared the metastasis of three colon carcinoma cell lines with 
different levels of sialyl lewis a (sLea) expression. They demonstrated that in nude 
mice the amount of sLea correlated with the metastatic potential of the cancer cells to 
the liver. By blocking sLea on the carcinoma cells with anti-sLea antibody, metastasis 
was inhibited (Sato et al. 1997). Figure 1.2B diagrammatically shows the interaction 
of selectins and their ligands. 
Examining expression levels of selectin and their ligands in human tissue, 
researchers have shown evidence of E-selectin expression in venules in breast 
carcinoma. This, however, was not the case for normal tissue. In addition the 
expression pattern of P-selectin was altered in cancerous breast endothelium compared 
to normal tissue (Fox et al. 1995; Matsuura et al. 1997). All these studies make a 
compelling case for the involvement of selectins and their ligands in metastasis.  
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1.3 Apoptosis Molecule - TRAIL 
TRAIL (also known as APO 2L or CD253) stands for Tumor Necrosis Factor 
(TNF)-Related Apoptosis-Inducing Ligand. TRAIL is a 60 kD type II transmembrane 
protein, first identified based on its sequence homology to the TNF and Fas Ligand 
(Pitti et al. 1996; Wiley et al. 1995). Five receptors are known to bind TRAIL (Figure 
1.3), two of which induce apoptosis via the caspase pathway upon binding and are 
known as the death receptors (DR4 or TRAIL-R1 and DR5 or TRAIL-R2) (Pan et al. 
1997a; Pan et al. 1997b; Screaton et al. 1997; Walczak et al. 1997). Two receptors that 
competitively bind TRAIL but do not induce apoptosis due to a missing or truncated 
cytoplasmic tail that is required to recruit the death domain, are called decoy receptors 
(DcR1 or TRAIL-R3 and DcR2 or TRAIL-R4) (Degli-Esposti et al. 1997a; Degli-
Esposti et al. 1997b; Sheridan et al. 1997). The fifth receptor is the low affinity 
receptor osteoprotegerin (OPG) (Truneh et al. 2000). OPG has a role in bone 
remodeling. However, based on TRAIL-R-/- mice experiments, TRAIL-OPG binding 
did not affect bone remodeling (Diehl et al. 2004; Finnberg et al. 2005). 
Expression of TRAIL and its receptors is found in different human tissues 
including spleen, thymus, prostate, testes, ovaries, peripheral blood lymphocytes, 
uterus and multiple tissues along the gastrointestinal tract, on an mRNA level 
(Walczak et al. 1997; Wiley et al. 1995). The Fas (CD95) system is tightly controlled 
by expression of FasL (CD95L). However, in the case of TRAIL, the expression ratio 
of death and decoy receptors does not seem to correspond to sensitivity towards 
TRAIL (Rana et al. 2009; Zhang et al. 1999). Hence, the control of TRAIL-mediated 
apoptosis is believed to be internal to the cell.  
 13 
Previous studies from TRAIL have shown that TRAIL exerts its cytotoxic 
effects on several cell lines. Unlike other members of the TNF family, TRAIL exerts 
its cytotoxic effects on transformed cells while sparing non-cancerous cells 
(Ashkenazi 2002; Fricker 1999; Held and Schulze-Osthoff 2001; Plasilova et al. 2002). 
Recombinant soluble human TRAIL has been shown to induce apoptosis in several 
cancer cell lines and mouse xenografts (Ashkenazi et al. 1999; Gazitt 1999; Mitsiades 
et al. 2001; Oikonomou et al. 2007; Walczak et al. 1999; Yu et al. 2000). These 
qualities make TRAIL a promising candidate for cancer therapy. 
Human Genomic Science (HGS) have developed humanized antibodies against 
DR4 and DR5. These antibodies HGS-ETR1 (against DR4) and HGS-ETR2 (against 
DR5) bind to the specific receptor and induce apoptosis in a manner similar to TRAIL 
(Duiker et al. 2006; Menoret et al. 2006; Pukac et al. 2005; Wakelee et al. 2010). HGS 
has been evaluating both antibodies and combination therapies with other 
chemotherapeutics in humans and has completed phase I clinical trials in patients with 
solid tumors and lymphomas (Duiker et al. 2006; Wakelee et al. 2010). HGS-ETR1 is 
currently in phase II of clinical trials for patients with solid tumors (www.hgsi.com). 
1.3.1 Apoptosis Signaling via TRAIL – Death Receptors 
Induction of apoptosis by TRAIL is a highly controlled process with a number 
of pro-apoptotic and anti-apoptotic proteins involved in regulating the process 
(Corazza et al. 2009). When TRAIL binds to the death receptors, a death-inducing 
signaling complex (DISC) is formed. (Walczak and Sprick 2001). Trimerization of the 
receptor leads to the recruitment of another death domain-containing molecule called 
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Fas-associated death domain (FADD) (Zhang et al. 2004). FADD binding to the 
receptor causes a conformational change, which exposes the death effector domain 
(DED) to interact with caspases (Sprick et al. 2002). 
Caspases are cysteine-dependent, aspartate-specific proteases which upon 
activation are able to cleave several different substrates (Thornberry and Lazebnik 
1998). They exist in their inactive form within the cell. Once recruited to the DISC (in 
case of caspase-8 and caspase-10) or the apoptosome (caspase-10), the caspase 
cascade is started by an autocatalytic activation (Baliga and Kumar 2003; Creagh and 
Martin 2001; Thornberry and Lazebnik 1998). For this cascade to eventually translate 
into apoptosis, inhibitors of apoptosis should not be activated (Evan and Littlewood 
1998). 
Cells, depending on the requirement for the activation of mitochondrial 
apoptosis pathway, are classified into two groups; type I and type II. Type II cells 
require the activation of mitochondrial apoptosis pathway (Figure 1.4) to amplify the 
signal whereas caspase activation by the DISC is sufficient to induce apoptosis in type 
I cells (Joza et al. 2001).  
The Bcl-2 family of proteins control the mitochondrial apoptosis pathway 
(Strasser 2005). Members of the Bcl-2 family of the protein are either pro-apoptotic or 
anti-apoptotic and share Bcl-2 homology domains (BH1 – BH4). The pro-survival 
members, e.g., Bcl-2, Bcl-XL and Mcl-1, contain all four BH domains. These proteins 
are associated with the mitochondrial outer membrane and prevent apoptosis. The pro-
apoptotic members like Bax, Bak and Bok destabilize mitochondrial membrane 
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integrity leading to release of pro-apoptotic factors from the mitochondrial inter-
membrane space. These pro-apoptotic factors in turn are activated by members of the 
“BH3-only” Bcl-2 subfamily. BH3-only proteins, e.g., Bid, Bim, Bmf, Puma and 
Noxa, are characterized by the fact that they only contain the third BH domain. BH3-
only proteins are activated in a number of different ways including triggering of CD95 
or TRAIL death receptors, DNA damage or different cellular stresses (Puthalakath et 
al. 2007; Villunger et al. 2003; Wei et al. 2000). Following crosslinking of DR4 or 
DR5, Bid is cleaved to truncated Bid (tBid) by DISC-activated Caspase-8 and -10. 
Binding of tBid to mitochondria initiates mitochondrial apoptotic events with the 
release of cytochrome C, Smac/DIABLO and other pro-apoptotic factors from the 
mitochondrial inter-membrane space (Suzuki et al. 2001a; Verhagen et al. 2000). 
Cytochrome C binds with Apaf-1 to form the “apoptosome” and the apoptosome 
formed serves to activate Caspase-9 (Riedl and Salvesen 2007). Smac/DIABLO in 
turn inhibit the action of inhibitor of apoptosis proteins (IAPs) (Verhagen et al. 2000). 
The X-linked inhibitor of apoptosis protein (XIAP) is a potent inhibitor of activated 
Caspase-3, 7 and 9 by inhibiting the autocatalytic step responsible for full activation of 
Caspase-3 (Eckelman et al. 2006; Suzuki et al. 2001b). Type II cells often express 
high levels of IAPs. As discussed earlier, the effect of IAPs can be counteracted by 
Smac/DIABLO, which might explain the requirement of a stronger apoptotic signal in 
type II cells. Figure 1.4 gives a pictorial summary of the signaling pathway. 
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1.4 Motivation and Overall Aims 
Devices have been proposed to deal with reducing the metastatic load from the 
circulation (Edelman et al. 1996; Fruhauf et al. 2001; Perseghin et al. 1997). These 
devices are all based on the principle of filtration. One such device uses a leukocyte 
depletion filter RC-400 to reduce the metastatic load. The device, though showing 
high efficiencies in removal of cancer cells, had some drawbacks. Such devices do not 
filter cells on a continuous basis and require frequent hospital visits. There is a 
possibility of accumulation of cancer cells between filtration treatments. In addition to 
the risk of cancer cell accumulation, the device is associated with patient discomfort 
and secondary infections due to the indwelling catheter.  
The proposed research aims at demonstrating the feasibility and utility of 
targeting metastatic cancer cells using naturally occurring interactions of E-selectin 
and cancer cells to deliver TRAIL. Two different approaches are developed here; the 
first involves capturing flowing cancer cells in a functionalized microtube while the 
second uses E-selectin and TRAIL decorated liposomes. 
Previously described methods rely on batch processing of blood to remove 
metastatic cancer cells. The proposed microtube device would allow screening of 
blood on a continuous basis, thus eliminating the possibility of accumulation of cancer 
cells between each treatment. It is envision that the device could ultimately be used as 
an implantable shunt that would “filter” blood for metastatic cancer cells and 
selectively neutralize them. This device is not intended to replace conventional 
chemotherapy but more as an adjunctive therapy or a combined therapy while 
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undergoing chemotherapy. We believe that targeting tumor cells with E-selectin to 
deliver TRAIL in the device/nanoscale liposomes would eliminate or at the very least 
reduce the metastatic load at the same time reducing the time of treatment and/or 
dosage of chemotherapeutic drugs. 
1.4.1 Specific Aims 
Aim 1: Demonstrate feasibility of a device capable of capturing cancer cells from the 
circulation and selectively inducing apoptosis to the captured cancer cells. 
Hypothesis 1: A surface functionalized with Selectin and TRAIL will kill 
cancer cells that interact with the functionalized surface.. 
Studies have shown that several tumor cells express functional ligands to selectins and 
have been shown to interact with various selectins (Barthel et al. 2007; Lafrenie et al. 
1993; Napier et al. 2007; Witz 2006; Witz 2008) while TRAIL has been shown to 
effectively neutralize several cancer cell lines (Appendix II, Table II.2), primary 
cancer cells and xenografts (Ashkenazi et al. 1999; Gazitt 1999; Oikonomou et al. 
2007; Plasilova et al. 2002). Creating an artificial surface, bearing selectin and TRAIL, 
would thus allow capturing of cancer cells in flow. While under the influence of shear 
force, the cells will translate in the direction of flow in a rolling-like behavior. While 
rolling, these cells will interact with TRAIL and receive an apoptotic signal, thus 
neutralizing the captured cell.  
Aim 2: Sensitize metastatic cancer cells to the effects of TRAIL using aspirin, thereby 
enhancing the efficacy of the microtube device and demonstrate feasibility in a 
combined treatment scenario. 
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Hypothesis 2:  Pre-treating cancer cells with aspirin will sensitize cancer cells 
to TRAIL thereby increasing the neutralization capability and feasibility in 
combined treatment scenarios.  
Treating cancer cells with drugs including aspirin (ASA) has been shown to sensitize 
cancer cells initially resistant to TRAIL and enhance the effect of TRAIL on cancer 
cells that are sensitive to TRAIL induced apoptosis.  (Cuello et al. 2001; Keane et al. 
1999; Koschny et al. 2007; Voelkel-Johnson et al. 2002). Pretreatment of cancer cells 
with such drugs would increase the efficacy of the device by sensitizing cancer cells 
and demonstrate the feasibility of using the device in combined treatment scenario. 
Aim 3: Demonstrate feasibility of using E-selectin and TRAIL-bound liposomes to 
selectively kill cancer cells in flow. 
Hypothesis 3: Conjugating E-selectin to liposomes will allow binding of 
liposomes to fast moving cells while TRAIL will specifically kill cancer cells. 
The clearance time of TRAIL is about 4 – 5 h and consequently large amount of 
TRAIL is required to maintain the active concentration (Xiang et al. 2004). 
Alternatively, liposomes have been shown to increase the circulation times of small 
proteins. Conjugating E-selectin to liposomes will facilitate fast moving cancer cells to 
bind to the liposomes while conjugating TRAIL would specifically kill cancer cells 
and improving the circulation time of TRAIL.  
Chapters 2 and 3 demonstrates the proof-of-concept for a device that is capable 
of capturing cancer cells under flow and killing them. I have investigated the effects of 
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the device on healthy cells (adult bone marrow, mono nuclear cells from peripheral 
blood and neutrophils) to evaluate side effects of the device on healthy cells and 
leukemic cells. Later in Chapter 3, application to cancer cells of epithelial origin is 
explored. The last part of Chapter 3, explores the effect of aspirin sensitization of 
cancer cells to TRAIL-mediated apoptosis. While Chapters 2 and 3 use of an 
implantable device, Chapter 4 works on developing a systemic TRAIL delivery 
system with nanoscale liposomes. Liposomes have an extended circulation time while 
TRAIL being a smaller molecule has very short half-life (~30 minutes). Using 
liposomes to deliver TRAIL would improve the circulation times and the fluidity of 
the liposomes would allow trimerization of the TRAIL molecule and its receptors that 
are essential to induce the apoptosis signal. A preliminary study with bortezomib co-
treatment is described in Appendix I. Bortezomib has been shown to be effective in 
treating multiple myeloma and sensitize cancer cells to TRAIL. Appendix II list 
potential cell lines that could be used to further develop the work described in this 
dissertation.  
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Figure 1.1: A schematic of the metastatic process.
 21 
  
C-type lectin domain
EGF-like domain
Short consensus 
repeat units
-COOH Cytoplasmic domain
-NH2
L-selectin E-selectin P-selectin
Figure 1.2: (A) Schematic of selectin structure. Three different selectins exist and 
share a similar structure. At the N-terminus is a carbohydrate binding site 
followed by an EGFlike domain and a series of short consensus repeat units
which give each selectin molecule its characteristic properties and finally a 
cytoplasmic domain. (B) Selectins and their ligands. The arrows indicate interaction 
between the molecules.
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Figure 1.3: Human TRAIL and its receptors. TRAIL bind to 5 known 
receptors. TRAIL-R1 and -R2 possess the intracellular death domain 
and are capable of inducing apoptosis while TRAIL-R3 and -R4 are 
incapable of inducing apoptosis. The fifth receptor is a low affinity 
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Figure 1.4 : The extrinsic and the intrinsic pathways of apoptosis. Upon binding 
of TRAIL to death receptors the receptors trimerize to form DISC by the recruit-
ment of FADD and procaspase- 8/10. Autocatalytic cleavage of these initiator 
caspases leads to the activators of the effector caspases, caspase-3 which leads 
to apoptosis. Active caspase-8/10 can cleave BID to truncated BID (tBID) which 
translocates to the mitochondria to release cytochrome C. Alternatively DNA 
damage can also trigger the release of cytochrome C by activating the pro-
apoptotic members of the Bcl-2 family proteins Bax and Bak. Together with Aparf 
1, dATP, procaspase-9 and cytochrom C form a complex apoptosome. Apopto-
some activated caspase-9 is able to activate caspase-3 and lead to apoptosis.
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2.0 Abstract 
The survival rate for patients with metastases vs. localized cancer is 
dramatically reduced, with most deaths being associated with the formation of 
secondary tumors. Circulating cancer cells interact with the endothelial lining of the 
vasculature via a series of adhesive interactions that facilitate tethering and firm 
adhesion of cancer cells in the initial steps of metastasis. TNF-related apoptosis-
inducing ligand (TRAIL) holds promise as a tumor-specific cancer therapeutic, by 
inducing a death signal by apoptosis via the caspase pathway. In this study I exploit 
this phenomenon to deliver a receptor-mediated apoptosis signal to leukemic cells 
adhesively rolling along a TRAIL and selectin-bearing surface. Results show that 
cancer cells exhibit selectin-mediated rolling in capillary flow chambers, and that the 
rolling velocities can be controlled by varying the E-selectin surface density and the 
applied shear stress. It was determined that a 1 hr rolling exposure to a functionalized 
TRAIL and E-selectin surface was sufficient to kill 30% of captured cells compared to 
static conditions in which 4 hr exposure was necessary to kill 30% of the cells. Thus, I 
conclude that rolling delivery is more effective than static exposure to a TRAIL-
immobilized surface. I have also verified that there is no significant effect of TRAIL 
on hematopoietic stem cells and other normal blood cells. This represents the first 
demonstration of a novel biomimetic method to capture metastatic cells from 
circulation and deliver an apoptotic signal. 
KEYWORDS: apoptosis, cancer, metastasis, TRAIL, E-selectin, rolling, cell 
adhesion. 
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2.1 Introduction 
Tumor metastasis consists of a series of discrete steps that move the tumor 
cells from the primary site to a distal location. The tumor cells must invade the 
surrounding tissue and enter either the bloodstream or the lymphatic system, survive 
the circulation and adhesively interact with the vasculature that facilitates tethering, 
rolling and eventually firm adhesion or arrest. Following arrest, the tumor cells 
extravasate into the distal site and grow into a secondary tumor (Chambers et al. 1995; 
Chambers et al. 2000; Chambers et al. 2001; MacDonald et al. 2002). Although 
surgery, radiation therapy and chemotherapy are effective in controlling many cancers 
at the primary site, the development of metastatic cancer signals a poor prognosis. The 
survival rate for patients with such metastatic cancers is dramatically reduced, with 
most deaths being associated with the formation of secondary tumors. This makes 
metastatic tumors an important factor in determining the outcome of the disease. 
Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) or 
Apo2L is a 60 kD, type II transmembrane protein identified on the basis of sequence 
homology to FasL and TNF. TRAIL is known to bind five known receptors: two of 
which are death receptors (DR4 and DR5) that signal apoptosis while the other three 
are decoy receptors (DcR1, DcR2 and DcR3) that do not signal apoptosis due to a 
shorter, non-functional cytoplasmic tail (Plasilova et al. 2002).  Unlike other members 
of the TNF family, TRAIL exerts its cytotoxic effects on malignant cells without any 
adverse effects on most non-cancerous cells (Ashkenazi 2002; Fricker 1999; Held and 
Schulze-Osthoff 2001; Plasilova et al. 2002) making TRAIL a promising therapeutic 
agent for cancer treatment.  Recombinant soluble human TRAIL has been shown to 
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induce apoptosis in several cancer cell lines and mouse xenografts (Ashkenazi et al. 
1999; Gazitt 1999; Mitsiades et al. 2001; Oikonomou et al. 2007; Walczak et al. 1999; 
Yu et al. 2000). Despite the broad range and specificity of TRAIL to induce apoptosis 
in cancerous cells, tagged TRAIL has been found to induce apoptosis in non-
cancerous human cells from the liver, brain and keratinocytes (Jo et al. 2000; Leverkus 
et al. 2000; Nitsch et al. 2000). Besides these documented side effects, Zamai et al. 
(Zamai et al. 2000) have suggested that his-tagged TRAIL may alter erythropoiesis. 
All these observations argue against systemic delivery of TRAIL. A delivery system 
where highly localized concentrations of TRAIL may be given to cancer cells without 
releasing TRAIL systemically is strongly warranted.  Existing devices that filter blood 
for cancerous cells have been associated with patient discomfort. Moreover, these 
devices do not filter blood on a continuous basis. This may lead to a buildup of tumor 
forming cancer cells between treatments (Edelman et al. 1996; Fruhauf et al. 2001; 
Perseghin et al. 1997). 
In this study, I demonstrate a novel biomimetic method to adhesively capture 
metastatic cancer cells from the peripheral circulation, expose the captured cells to a 
high concentration of TRAIL and induce an apoptotic signal, thus neutralizing the 
cancer cell (Figure 2.1A). 
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2.2 Materials and Methods 
2.2.1 Reagents and antibodies 
Human serum albumin (HSA), bovine serum albumin (BSA), HEPES, EDTA 
and calcium carbonate (CaCO3) were all obtained from Sigma-Aldrich (St Louis, MO). 
RPMI 1640 cell culture media, fetal bovine serum (FBS), 0.25% trypsin, Penicillin-
Streptomycin (PenStrep), Hank’s balanced salt solution (HBSS) and phosphate-
buffered saline (PBS) and Dynal® CD34+ Progenitor Cell Isolation System were all 
obtained from Invitrogen (Grand Island, NY). His-tagged recombinant human TRAIL, 
human methylcellulose complete media, recombinant human E-selectin-IgG chimera 
and TACS Annexin-V FITC Apoptosis Detection Kit were purchased from R&D 
Systems (Minneapolis, MN). Protein-G and anti-His tag antibody were purchased 
from EMD Biosciences (San Diego, CA). Ficoll-Paque!PLUS was obtained from GE 
Healthcare Bio-Sciences Corp. (Piscataway, NJ). Mouse anti-human TRAIL 
conjugated to phycoerythrin (PE) and Mouse anti-human E-selectin conjugated to 
fluorescein isothiocyanate (FITC) antibody were purchased from Abcam Inc. 
(Cambridge, MA). Mouse anti-Human TRAIL DcR1, DcR2, DcR3, DR4 and DR5, all 
conjugated to PE, were purchased from Biolegend (San Diego, CA). Quantum Simply 
Cellular (QSC) beads were purchased from Bangs Laboratories Inc. (Fisher, IN). 
2.2.2 Cell lines and cell culture 
Acute Myeloid Leukemic (AML) cell line HL60 (ATCC number CCL-240), 
KG1a (ATCC number CCL-264.1) and colon cancer cell line Colo205 (ATCC number 
CCL-222) were obtained from ATCC (Manassas, VA). Two prostate cancer cell lines 
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DU145 and PC3 were obtained from Prof. Yi Fen-Lee (University of Rochester). 
These cell lines were cultured in RPMI 1640 supplemented with 2mM L-glutamine, 
25mM HEPES, 10% v/v FBS and 100 U/mL PenStrep (complete media) under 
humidified conditions at 37˚C and 5% CO2. Cells in suspension (KG1a and HL60) 
were cultured such that the cell count did not exceed 1 x 106 cells/mL while the 
adherent cells were maintained such that 90% confluence was not exceeded.  
2.2.3 Cell preparation for rolling experiments 
Adherent cell lines (Colo205, DU145 and PC3) were mildly trypsinized for 5 
minutes, following which the cells were allowed to sit in complete media, 5% CO2 and 
humidified conditions for up to 5 hours before use to ensure re-expression of surface 
receptors. All cells (including HL60 and KG1a) were washed twice with PBS at 200g 
in Allegra X-22 refrigerated centrifuge at 4˚C and resuspended in the flow buffer at a 
concentration of 1 x 106 cells/mL. The flow buffer consisted of HBSS without Ca2+ 
and Mg2+ supplemented with 0.5% w/v HSA, 10mM HEPES and 2mM CaCO3 
(HBSS+).  For rolling experiments, at least 90% viability of cells was confirmed by 
trypan blue exclusion dye. 
2.2.4 Preparation of immobilized protein surfaces 
Recombinant human E-selectin Fc chimera was dissolved in PBS to a final 
concentration of 100 !g/mL. In addition, stock solutions of TRAIL, protein-G and 
anti-His tag antibody in PBS were prepared at 20 !g/mL, 100 !g/mL and 200 !g/mL 
respectively. Aliquots of the stock solutions were stored at –20 ºC and used as needed 
within 60 days. The surface was first incubated with 10 !g/mL protein-G solution for 
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1.5 hours, followed by a 2 hour incubation with selectin chimera (0.1 - 5 !g/mL) or a 
combination of selectin chimera and anti-His tag antibody  (5 !g/mL and 10 !g/mL 
respectively), and then the surface was incubated with 2 - 20 !g/mL TRAIL solution. 
Each incubation step was followed with three washes with PBS. All incubations were 
conducted at room temperature and successful immobilization was confirmed by 
immunofluorescence. 
2.2.5 Mononuclear cell (MNC) and CD34+ hematopoietic stem and progenitor cell 
(HSPC) isolation 
All human subject protocols have been approved by the Research Subjects 
Review Board (RSRB) of the University of Rochester. Adult bone marrow (ABM) 
and peripheral human blood were collected from healthy willing donors after informed 
consent into vacutainer tubes containing heparin and allowed to equilibrate at room 
temperature before use. ABM cells were used to evaluate the colony forming potential 
with TRAIL treatment while mononuclear cells (MNC) from peripheral blood were 
collected for flow studies as described later. Briefly, 10 – 15 mL of ABM was diluted 
with PBS to a final volume of 35 mL, then carefully layered over 10 mL Ficoll-Paque 
PLUS and centrifuged at 480xg for 30 minutes. Mononuclear cells (MNC) were 
collected and washed twice with PBS before being resuspended in flow buffer to the 
desired final concentration. A similar procedure was followed to isolated MNCs from 
peripheral blood and used for rolling experiments as described later.  
The Dynal® beads cell selection system was used for isolation of CD34+ 
HSPCs as per manufacturer’s instructions. Briefly, anti-human CD34 antibody 
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conjugated to 4.5!m-diameter paramagnetic beads was added to MNC suspension at 4 
x 107 to 4 x 108 cells/mL and allowed to incubate at 4ºC for 30 minutes before being 
placed in a magnetic field. The paramagnetic beads, attached to CD34+ cells, 
precipitated within the magnetic field so that the unselected CD34- cells could be 
removed and collected. The CD34+ cells were released from the antibody-bead 
complex using a competitive peptide, washed and resuspended in HBSS+ to the 
desired final concentration for experimentation. Mean CD34+ cell purity used for 
experiments was about 70% as determined by flow cytometry. 
2.2.6 Colony forming assay 
5 x 104 cells/mL of MNCs isolated from ABM cells were suspended in 3 mL 
of human methylcellulose complete media. The media purchased contained pre-added 
recombinant human stem cell factor (50 ng/mL), recombinant human 
granulocyte/macrophage-colony stimulating factor (GM-CSF) (10 ng/mL), 
recombinant human interleukin (IL) -3 (10 ng/mL) and recombinant human 
erythropoietin (Epo) (3 U/mL). Soluble TRAIL was added at a concentration of 2 
µg/mL and mixed to ensure uniform distribution of cells and TRAIL. After 14 days, 
granulocyte/macrophage and erythroid colonies were counted. All experiments were 
performed in duplicate.  
2.2.7 Receptor surface expression 
The average number of death and decoy receptors on cancer cells was 
determined by flow cytometry calibration with QSC beads (Bangs Labs, Fishers, IN). 
Briefly, beads were incubated for 45 minutes with a PE-conjugated antibody specific 
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to the antigen on the beads. Beads with different numbers of antibody binding sites 
were mixed and run through a flow cytometer. Populations of beads corresponding to 
different numbers of antibody binding sites yield progressively increasing peaks in the 
fluorescence channel corresponding to the number of antibody binding sites. Median 
value of each peak was obtained using FlowJo v8.7.1. Using these median fluorescent 
channel values and the number of antibody binding sites (reported by the 
manufacturer), a calibration curve was generated using QuickCal v2.3 (Bangs Labs, 
Fishers, IN).  
Following the calibration step, cancer cell lines were incubated with PE 
conjugated anti-human DcR1, DcR2, DcR3, DR4 and DR5 on a rotating platform for 
45 minutes at room temperature. These cells were then analyzed on a Guava EasyCyte 
Mini flow cytometer. The peak fluorescence channel was recorded for each receptor. 
From the calibration curve, the peak was converted to the number of death and decoy 
receptors. Three separate measurements were performed for each cell type and 
receptor. 
2.2.8 Static experiments 
Cancer cell lines were cultured in complete media with soluble TRAIL (0 – 2 
!g/mL) in a 24 well plate for 48 hours. In a similar fashion, the effect of TRAIL on 
ABM was studied by culturing ABM with TRAIL at a concentration of 2 !g/mL. In 
some experiments multi-well plates were functionalized with proteins as described 
earlier. Cells were then cultured on the functionalized surface in complete media, 37˚C, 
5% CO2 and humidified conditions for up to 48 hours.  
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2.2.9 Rolling experiments  
A 50 cm long, 300 !m internal diameter Micro-Renathane tubing (Figure 
2.1B) was obtained from Braintree Scientific (Braintree, MA), and secured to the stage 
of the Olympus IX81 motorized inverted research microscope (Olympus America Inc, 
Melville, NY). The microscope was equipped with a CCD camera (Model No: KP-
M1AN, Hitachi, Japan) connected to either a S-VHS videocassette recorder (Model 
No: SVO-9500MD2, Sony Electronics, Park Ridge, NJ) or a DVD recorder (Model 
No: DVO-1000MD, Sony Electronics, Park Ridge, NJ) to facilitate image capture for 
offline analysis. A syringe pump (KDS 230, IITC Life Science, Woodland Hills, CA) 
was used to control the flow rate of the cell suspension. Cells were loaded on the 
surface at a shear stress of 0.5-1 dyne/cm2 for 3 minutes following which the flow 
experiment was performed. Flow experiments on functionalized capillary flow 
chamber surfaces were performed at 2.5 dynes/cm2, for a period of 1 hour. At the end 
of 1 hour, cells were categorized into two fractions, “cells on surface” – cells that were 
rolling on or remained on the surface at the end of the experimentation period and 
“cells in flow” – cells that were collected in the syringe.  
The cells on the surface were harvested using 5 mM EDTA and air embolism 
at 10 dyne/cm2. These cells were then either seeded at 100,000 cells/mL, and then 
counted at day 4 or cultured and analyzed by Annexin-V assay. E-selectin and His-tag 
antibody (without TRAIL) functionalized surfaces were used as negative controls. 
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2.2.10 Data analysis 
“Rolling” cells were defined as those observed to translate in the direction of 
flow with an average velocity less than 50% of the calculated hydrodynamic free 
stream velocity. Rolling flux was determined by counting the number of cells crossing 
a line drawn in the field of view perpendicular to the flow direction, over a period of 
one minute. 
 All cell experiments were analyzed by Annexin-V apoptosis assay on a BD 
FACSCaliber flow cytometer or the Guava EasyCyte Mini. Instructions provided by 
the manufacturer were followed to prepare samples for flow cytometry. Briefly, 
Annexin-V is a protein that binds to negatively charged phospholipids. Flipping of 
phosphatidylserine (PS) in the cell membrane to the extracellular side (enabling 
Annexin-V to bind to PS) is considered an early event in apoptosis and is considered 
important for macrophage recognition of apoptotic cells. Cells that label for propidium 
iodide (PI), a DNA stain, possess a compromised cell membrane. Based on the dye 
taken up by cells, they are classified into four categories: viable cells (negative for 
Annexin-V and PI), early apoptotic cells (positive for Annexin-V only), late apoptotic 
cells (positive for Annexin-V and PI) and necrotic cells (positive for PI only). 
Where appropriate, the student’s t-test was employed at significance level of " 
= 0.05. All statistical analyses were performed using GraphPad Prism 5.0a for Mac OS 
X GraphPad Software, San Diego, CA USA www.graphpad.com. 
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2.3 Results 
2.3.1 Cancer cells exhibit a shear-dependent rolling on functionalized E-selectin. 
HL60 cells were infused into a capillary tube 50 cm long and 300 µm internal 
diameter functionalized with E-selectin chimera at different shear stresses ranging 
from 1 – 10 dynes/cm2. The surface density of E-selectin molecule was varied by 
incubating the tube with different concentrations of E-selectin solution (0.1 µg/mL – 
10 µg/mL) at room temperature. Cells were suspended in flow buffer such that the 
concentration of cells was 1 x 106 cells/mL and were loaded on the surface at 0.5 
dyne/cm2. Shear stress was applied to the cells by flowing fluid and recorded for 
offline analysis.  The average rolling velocity for each experiment was computed and 
the rolling flux was determined. Rolling was observed at 1 µg/mL and 5 µg/mL 
incubation concentrations of E-selectin. No adhesive interaction was observed with 
0.1 µg/mL E-selectin concentration while extremely slow rolling was observed at 5 
µg/mL of E-selectin. At higher concentrations of E-selectin (10 µg/mL E-selectin and 
higher) distinguishing firmly adherent and rolling cells became difficult. From these 
experiments I found that 5 µg/mL of E-selectin gave stable rolling with relatively slow 
rolling velocities. HL60 cell line showed a shear-dependent rolling velocity and 
rolling flux (Figure 2.1C). By varying the E-selectin site density I was able to achieve 
different rolling velocities at a given shear stress. These results were used determine a 
suitable E-selectin density (5 mg/mL) to produce low rolling velocities at a 
representative wall shear stress.  
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2.3.2 Cells show different sensitivity to soluble TRAIL. 
With reports of TRAIL-resistant cancer cells (Bouralexis et al. 2003; Ng and 
Bonavida 2002; Zisman et al. 2001), I investigated the effect of soluble TRAIL on our 
model cell lines, HL60, KG1a, Colo205, DU145 and PC3. Cells at a concentration of 
300,000 – 500,000 cells/mL were cultured in complete media at 37˚C, 5% CO2 and 
humidified conditions with varying concentrations (0 - 2 !g/mL) of TRAIL for a 
period of 48 hours. These cells were then collected and examined for viability by 
Annexin-V assay (Figure 2.2A – E). Since the primary objective of the work presented 
here is to neutralize cancer cells, irrespective of the mode of death, I have compared 
viable cell proportions in the treated and untreated samples.   
In general, all cell lines showed a decrease in viability when treated with 
TRAIL. The cell lines Colo205 and HL60 were the most sensitive to TRAIL while 
KG1a and DU145 showed the most resistance. The PC3 cell line had sensitivity 
intermediate of HL60 and DU145. Among the leukemic cell lines, KG1a was more 
resistant to TRAIL than HL60. Even at 1.8!g/mL about 70% of KG1a were viable, 
while the HL60 reached a plateau in viability at 0.1 !g/mL. Viability observed at 0.1 
!g/mL was around 15 – 20%. Increasing the TRAIL dosage beyond 0.1 !g/mL did not 
decrease the viability significantly, while a further decrease in viability of KG1a may 
be possible at higher dosages of TRAIL.  
Colo205 showed a plateau similar to that of HL60 at 0.1 !g/mL with around 
15% viable cells. The prostate cancer cell lines PC3 and DU145 seemed to be 
relatively more resistant to TRAIL and showed a plateau at 0.1 !g/mL of TRAIL. Of 
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the two prostate cancer cell lines, DU145 was more resistance to soluble TRAIL while 
PC3 cells showed resistance intermediate to that of KG1a and DU145 cell lines.  
In a separate set of experiments, the cells were incubated with PE-conjugated 
antibody to the death and decoy receptors present on the cell membrane to quantify the 
number of receptors present on the cell membrane. I did not see any significant 
correlation between the numbers of death and decoy receptors and the sensitivity of 
cancer cells towards soluble TRAIL. For instance, cell lines that were most sensitive 
to TRAIL expressed comparable total numbers of death and decoy receptors, while the 
more resistant cell lines, DU145, has more death receptors and decoy receptors. The 
average receptors counts from three independent experiments are summarized in Table 
1.1. Values represented are average ± SD. 
2.3.3 Soluble TRAIL has no significant effect on adult bone marrow cells.  
In order to evaluate the effect of TRAIL on viability of ABM cells, ABM cells 
isolated as described in the methods section, were treated with 2 !g/mL of soluble 
TRAIL and cultured at 37˚C and humidified conditions for 48 hours. These cells were 
then collected and analyzed by Annexin-V assay for viability. Treating the ABM cells 
with this high dose of TRAIL (median lethal dose, 50% or LD50 ~12 ng) had 
negligible effect on the viability of both CD34+ and CD34- bone marrow cells (Figure 
2.3A, B).   
Zamai et al. (Zamai et al. 2000) have suggested that TRAIL may affect 
erythropoiesis. Since most blood cells are derived from CD34+ hematopoietic stem 
cells, MNCs isolated from bone marrow was used for this experiment. In order to 
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evaluate the ability of TRAIL to affect differentiation of CD34+ hematopoietic stem 
cells to erythroid and granulocyte – macrophage colonies, MNCs isolated from bone 
marrow was subjected to long term (14 days) culture in semi-solid media with TRAIL 
at 2 !g/mL as described in material and methods. No statistically difference in the 
number of colonies formed in the TRAIL treated compared to the untreated samples 
was seen, however a small decrease in the number of colony forming units – 
granulocyte, monocytes (CFU-GM) with a small increase in burst forming units – 
erythroid (BFU-E) of the treated samples was observed (Figure 2.3C, D). Consistent 
with our results Palsilova et al. (Plasilova et al. 2002) have reported no adverse effects 
of his-tagged TRAIL on the viability of ABM however they observed reduced the 
number of myeloid colonies (CFU-GM).  
2.3.4 Immobilized TRAIL and selectin surface produces significant killing of HL60 
cells. 
Tissue culture grade polystyrene surfaces were functionalized with TRAIL and 
selectin to test the efficacy of the proposed system under static conditions. A high rate 
of apoptosis for HL60 cells was observed, while the more TRAIL resistant, KG1a 
cells showed no significant difference in apoptosis (Figure 2.4A, B). Cells at a 
concentration of 2.5-3.0 x 105 cells/mL were seeded in each experiment and cultured 
at 37˚C and 5% CO2 under humidified conditions. Similar experiments with surfaces 
functionalized with TRAIL alone and E-selectin alone were also performed at two 
different incubation concentrations of TRAIL. When incubated on these surfaces, 
HL60 cells demonstrated a dose-dependent rate of cell death on TRAIL alone (Figure 
 55 
2.4C). No significant effect on viability was observed in the case of E-selectin and 
His-tag Ab alone (data not shown).  
In a separate experiment, the effect of static contact time of cells with a surface 
functionalized with TRAIL and E-selectin for 1 hour and 4 hours (Figure 2.5B) was 
studied. No significant kill was observed after 1 hour static exposure to TRAIL and E-
selectin immobilized surface, while a 28% decrease in viability was observed after 4 
hour static exposure. No significant kill was observed in both 1 hour and 4 hour static 
exposure to surfaces lacking the TRAIL molecule. 
2.3.5 Flow over combined surface for one-hour kills about 30% of HL60 cells 
without significant effects on MNCs. 
HL60 cells were washed in 1X PBS and resuspended in flow buffer at a 
concentration of 1x106 cells/mL. These cells were loaded onto the functionalized 
surfaces at wall shear stress of 0.5 - 1 dynes/cm2 for about 3 minutes after which the 
shear stress was increased to 2.5 dynes/cm2. The loading step promotes initial cell 
contact with the surface. Cells were perfused for 1 hour in a capillary tube (300 !m 
internal diameter and 50 cm length) functionalized with proteins. On average, about 
10% of the total perfused cells interacted adhesively with the surface and saturated the 
surface within a few minutes. At the end of 1 hour, the cells present on the surface of 
each capillary flow chamber were collected using 5mM EDTA and air embolism at 10 
dynes/cm2. The harvested cells were washed three times in PBS, counted and re-
suspended in RPMI complete media at 105 cells/mL and cultured either for four days 
and counted or cultured for one day and analyzed by Annexin-V assay for viability. 
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The cells counts after four days are shown in Figure 2.5C. A 35% difference in cell 
number at day 4 was observed between the cells collected from the combined TRAIL 
and E-selectin surface and the control surface (E-selectin and His-tag Ab). 
Significance was determined by the student t-test and a p < 0.001 was determined. No 
significant apoptotic effect was seen immediately after the rolling experiment. 
In the case where cells were cultured for 24 hours followed by the Annexin-V 
assay, a 30% difference in viable cells was seen between the cells harvested from the 
control, E-selectin and anti-His tag Ab, and the combined TRAIL and E-selectin 
surface (Figure 2.5D). The E-selectin + His-tag Ab surface showed the same viability 
as the unrolled cells.  Figure 2.5A is a representative plot of the original flow 
cytometry data. The results are divided into four quadrants with the lower left 
indicating viable cells, lower right indicating early apoptotic, upper right indicating 
late apoptotic and upper left indicating necrotic cells. Cells collected in the syringe at 
the end of the experiment had viability similar to the control cells suggesting little to 
no leaching of TRAIL from the surface (data not shown). 
Blood cells express selectin ligands and as a result may interact with the 
functionalized surface. To ascertain the effects of non-cancerous cells that may 
interact adhesively with the TRAIL and E-selectin surface, MNCs isolated from fresh 
human blood were allowed to flow over the functionalized micro capillary surfaces for 
1 hour at a wall shear stress 2.5 dyne/cm2. Cells were then collected using air 
embolism and 5mM EDTA, washed and cultured for 6 hours followed by the 
Annexin-V assay. No significant difference in viability was observed in cells that 
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rolled over the combined TRAIL and E-selectin surface and the E-selectin surface 
lacking TRAIL (Figure 2.5E).  
No significant cell binding on surfaces immobilized with protein-G, protein-G 
& anti-His tag antibody, anti-His tag antibody only, His-tag antibody coupled TRAIL 
and capillary flow chamber without any protein was seen. The adherent cells harvested 
from these tubes were not sufficient in number to perform analysis (100-500 cells). 
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2.4 Discussion 
In this study I demonstrate for the first time, a novel biomimetic method to 
capture metastatic cancer cells under flow via adhesive interactions with selectins and 
induce an apoptotic signal to captured cells. Our results suggest that by rolling cancer 
cells over the functionalized surface we can induce an apoptotic signal to a greater 
population of targeted cells than cells under static conditions. 
Cancer cells interact with the endothelial lining of the vasculature by a variety 
of adhesion molecules that facilitate tethering and arrest of blood-borne cancer cells to 
the blood vessel wall as the initial step in metastatic tumor formation. The initial 
contact between the cancer cell and the vasculature is mediated by the selectin group 
(L-, P- and E-selectin) of glycoproteins (Goetz et al. 1996; Kim et al. 1999; Orr and 
Wang 2001; Orr et al. 2000; Waugh and Evans 1979).  This contact with the 
endothelium initiates a cascade of activation events, similar to that of neutrophil 
recruitment during inflammation, and ultimately leads to the development of a 
metastatic tumor (Orr et al. 2000).  
Sipkins et at. (Sipkins et al. 2005) have characterized bone marrow 
microdomains susceptible to tumor engraftment. Using immunofluorescence they 
mapped the spatial distribution of adhesion molecules on endothelial cells and the 
chemoattractant stromal-cell-derived factor 1 (SDF-1). Then using a leukemic cell line, 
they showed that cell homing and engraftment correlated with the spatial distribution 
of E-selectin and SDF-1. Cells that were inhibited from homing to bone marrow by 
disrupting the interaction between SDF1 and its receptor CXCR4 remained in 
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peripheral circulation. This study suggests the potential for using our device to 
adhesively capture cancer cells in peripheral circulation and induce an apoptotic signal 
to them; hence preventing or reducing the metastatic load. 
Devices that reduce the blood-borne metastatic load have been proposed by 
several researchers (Edelman et al. 1996; Fruhauf et al. 2001; Perseghin et al. 1997). 
These devices require the passing of blood through a mechanical filter. Though these 
devices are highly efficient in filtering cancer cells from peripheral circulation, they 
have inherent limitations. Being external devices, these devices require catheterization, 
which increases patient discomfort and chances of secondary infection. In addition, 
filtration of cells is not done on a continuous basis and consequently may lead to 
accumulation of potential tumor-forming cancer cells in the circulation between 
treatments. A shorter version of the proposed device potentially eliminates these 
problems by making the device implantable. This would allow screening of cancer 
cells on a continuous basis. The device may be customized by functionalizing the 
surface with specific chemoattractants, proteins and small peptides or molecules to 
target specific cell types, thus extending the utility of the device.   
The King research group has recently shown that using a P-selectin coated tube 
they were able to enrich CD34+ hematopoietic stem cells from peripheral circulation 
of G-CSF-treated rats (Wojciechowski et al. 2008) and have shown that the same 
method can also be used to enrich CD34+ hematopoietic stem cells from human bone 
marrow (Charles et al. 2007; Narasipura et al. 2008). Cells collected in this manner 
may be used for stem cell transplants to leukemic patients. Unlike allogeneic 
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transplants, wherein stem cells are collected from a different donor, autologous 
transplants, wherein cells are collected from the patient, do not have the complication 
of immune rejection although autologous transplants have an associated risk of 
reintroducing cancer cells. The proposed device may be used ex-vivo to capture and 
neutralize cancer cells before autologous stem cell transplant to the patient. The device 
may also be used to filter and neutralize cancer stem cells that are believed to be 
tumorigenic in contrast to the bulk of cancerous cells that are non-tumorigenic (Huntly 
and Gilliland 2005; Li et al. 2007; Park et al. 1971).  
The TRAIL receptor surface expression I have measured, do not show a 
correlation with sensitivity towards TRAIL. The more resistant cell lines such as 
KG1a and DU145 had a greater number of death receptors than decoy receptors. In 
general, the more resistant cell lines, DU145 and KG1a both expressed a higher 
number of death receptors while the more sensitive cell lines PC3 and HL60 expressed 
lower number of death receptors. These observations suggest that the ratio of death to 
decoy receptors may not play an important role in determining the sensitivity of cancer 
cells towards TRAIL and that there is some intrinsic mechanism (such as upregulated 
expression of inhibitors of apoptosis) that makes cells more resistant to TRAIL.  
I have demonstrated that it is possible to kill about 30% of the rolling cells 
using the proposed method with a very short exposure to TRAIL. Wojciechowski and 
Sarelius showed that in the case of leukocyte trafficking; only about 10% of the 
arrested cells manage to transmigrate through the endothelial lining. The remainder of 
activated leukocytes eventually re-enter the blood flow (Wojciechowski and Sarelius 
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2005). If the experiments were conducted in a closed loop, this would allow multiple 
passes of cells over the surface and if conducted over longer periods of time, would 
yield a higher kill rate that may substantially reduce the metastatic load.  From the 
available literature, I have identified various cancer cell lines that are sensitive to 
selectins and TRAIL. Cell lines showing reactivity towards both molecules are 
identified as potential targets for further experimentation (Appendix II).  
Recently, reports of chemotherapeutic drugs, when used in sub-lethal doses, 
sensitize many cancer cell lines to TRAIL. These drugs when used in combination 
with TRAIL are shown to have additive and super-additive effects on cancer cells 
(Cuello et al. 2001; Keane et al. 1999; Mizutani et al. 2001). The proposed device 
could be used in conjunction with other treatments, thereby increasing the efficacy of 
the combined treatment. Literature also suggests that cancer cells may acquire 
resistance towards chemotherapy or radiotherapy by limiting drug uptake through the 
cell membrane or developing a DNA repair mechanism. Resistant cells when treated 
with TRAIL were found to undergo apoptosis. The same principle may be applied to 
cells that become resistant to either chemotherapy by treating with TRAIL, thereby 
expanding the utility of the device. 
Of particular interest is the fact that cells rolling over a surface functionalized 
with TRAIL and E-selectin for 1 hour produces a kill rate comparable to cells sitting 
on a similar functionalized surface for about 4 hours. It should be noted that the 
surfaces used in the two cases were different types of plastics, however the incubation 
concentrations of the proteins was the same. To obtain an estimate of the amount of 
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TRAIL present on the two different plastic surfaces, the surfaces were incubated with 
fluorescently labeled antibody against TRAIL and the mean fluorescence intensities 
were measured using an intensified camera. Background-subtracted mean florescence 
intensity for the polystyrene surface was 988.53 ± 47.42 and that for the tube was 
684.02 ± 14.72. These results indicate that the polystyrene surface adsorbed more 
TRAIL than the tube. As indicated by the relative fluorescence intensity, cells resting 
on the polystyrene surface are exposed to a greater local concentration of TRAIL than 
those rolling on the capillary flow chamber. From the data, I may conclude that it 
would take longer than 4 hours under static conditions to achieve close to 30% kill. 
Note that HL60 cells exhibit a dose-dependent decrease in viability when subjected to 
immobilized TRAIL (Figure 2.4C) although a dose response was not observed with 
soluble TRAIL (Figure 2.2B). Recall that the rolling cells were exposed to the TRAIL 
surface for only 1 hour and resulted in a 30% kill rate while a similar effect was seen 
at 4 hours when resting on a similarly functionalized surface. This observation may be 
understood by considering the relatively small surface area that is available for the 
receptors to interact with the surface. Additionally TRAIL receptors would likely need 
to diffuse to this small available area and bind to TRAIL before any apoptotic signal is 
induced, while a rolling cell, over the duration of rolling, presents the entire cell 
surface to the functionalized device. This eliminates the need for receptor diffusion to 
the site where TRAIL is present in order to signal apoptosis. Moreover, rolling may be 
delivering repeated “on” signals for apoptosis through periodic ligation and 
disassociation that may have a cumulative effect and enhance the rate of apoptosis. 
Thus, a selectin-mediated rolling delivery system may ultimately reduce the time to 
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induce the apoptotic signal by four-fold. In another set of experiments, a time-
dependent progression of cells from early to late apoptotic stage was observed (data 
not shown). 
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2.5 Conclusions 
In this study, I have demonstrated a novel biomimetic method to capture blood 
borne metastatic cancer cells from peripheral circulation and induce an apoptotic 
signal to them without an apoptotic effect on healthy MNCs in blood or ABM cells. 
With a very short exposure to TRAIL a kill rate of about 30% compared to control 
was achieved. To achieve a similar kill rate under static conditions, the cells must be 
in contact with the surface for 4 hours, thus I have demonstrated a more efficient 
method of delivering an apoptotic signal to metastatic cancer cells. This method may 
be tailored to capture specific cancer cells by functionalizing the surface with small 
peptides or other protein molecules that may be more selective at capturing cells. 
Small molecule replacements would be more stable thereby increasing the shelf life of 
the device. In addition, the molecules may be customized to capture specific cell types. 
Cells captured in this manner may then be reprogrammed or neutralized before being 
released into the circulation. The same technology may be utilized to capture and 
enrich rare cells from peripheral circulation, which may then be used for clinical 
research. The proposed device when used as described in this work may significantly 
reduce metastatic load and potentially improve cancer treatments. 
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Figure 2.1 : (A) Schematic of the two-receptor system for capture of cancer 
cells from peripheral circulation and induction of apoptosis signal to the cap-
tured cells. (B) Prototype capillary flow chamber which is functionalized with 
TRAIL and E-selectin. This tube has been filled with dye to aid viewing. (C) 
Rolling velocity and rolling flux of HL60 cells for two different concentrations of 
E-selectin as a function of shear stress. The data plotted is average ± SEM 
(n=3). 
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Figure 2.3 : Viability and differentiation of ABM. Cells were treated with 2 μg/mL of 
TRAIL in media and cultured for 48 hours at 37°C, 5% CO2 and humidified conditions. 
Dark bars represent the untreated cells while the lighter bars represent the treated 
cells. (A) Viability of CD34+ cells, (B) viability of CD34- cells, (C) colony counts for 
treated and untreated MNCs (P>0.05) and (D) BFU-E and CFU-GM as seen under 
light microscope in untreated and the treated samples (scale bar = 100 μm). The 
values shown are average ± SEM (n=3). Arrows indicate respective colonies. 
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Figure 2.4: Effect of E-selectin and TRAIL on functionalized polystyrene surfaces. 
Surfaces were functionalized with 2.5 μg/mL E-selectin and 5 μg/mL of TRAIL. Cells 
were incubated at 37°C, 5% CO2 and humidified conditions under static conditions 
for 48 hours. The results shown are average ± SEM (n=3). (A) KG1a and (B) HL60. 
(C) Dose dependency of HL60 on TRAIL immobilized on a polystyrene surface. 
Surfaces were functionalized with 2 μg/mL and 5 μg/mL of TRAIL and cultured under 
static conditions at 37°C, 5% CO2 and humidified conditions for 44 hours. The 
results are average ± SEM (n=3). ***P<0.001, *P < 0.05. 
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Figure 2.5: Effect of TRAIL and E-selectin functionalized surfaces on killing HL60 
cells. The surfaces were incubated with 10 μg/mL protein-G, 10 μg/mL of His-tag 
Ab, 5 μg/mL of E-selectin and 20 μg/mL TRAIL as described earlier. (A) Repre-
sentative flow cytometry plots.
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Figure 2.5: (B) Under static loading conditions for 1 h and 4 h (n=2), *P<0.05. (C) Cell 
counts at day four following 1 h of rolling on functionalized surface. Each experiment 
was performed in duplicate, (n=5), ***P<0.001. (D) Percent dead cells (100% - % viable 
cells) after 1 h of rolling on the functionalized surface followed by 24 h incubation. An 
average difference of 30.08 ± 0.64% between E-selectin + His-tag Ab surface and the 
combined surface of TRAIL and E-selectin is observed (n=3), ***P<0.001 (E) Percent 
viable MNCs after 1 h rolling on functionalized surfaces. Cells were harvested using air 
embolism and 5mM EDTA, washed and cultured for 6 h. MNCs were isolated from 
freshly collected human blood (n=3). All results are average ± SEM. 
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Chapter 3 Inducing Apoptosis in Rolling Cancer Cells: A 
combined therapy with Aspirin and immobilized TRAIL & 
E-selectin. 
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3.0 Abstract 
Secondary tumors formed because of metastasis are the major cause of cancer-related 
deaths. One of the ways in which cancer cells leave the vessels is similar to that of 
leukocytes under an inflammatory response. Cancer cells interact with the vasculature 
by adhesive interactions that facilitate rolling mediated by selectins expressed on the 
endothelium, firm adhesion and eventually transmigration to form secondary tumors. 
TNF-related apoptosis-inducing ligand (TRAIL) or APO2L holds promise as a tumor-
specific cancer therapeutic, by inducing apoptosis via the extrinsic pathway. In this 
study, I exploit the interaction of cancer cells with selectins and TRAIL to deliver a 
receptor-mediated apoptosis signal to captured cancer cells. Building on the work 
presented in Chapter 2, In the present study, I extend the method to colon carcinoma 
which when pretreated with 1 mM aspirin, followed by rolling over the combined 
surface, a 95% difference in the number of viable cells was found after 3 days between 
the cells that rolled over the combined TRAIL and E-selectin surface compared to the 
control surface lacking TRAIL. These synergistic results with aspirin pretreatment 
suggest a promising combined treatment scenario for an implantable blood-contacting 
device. While rolling over the combined surface of E-selectin and TRAIL, PMNs shed 
L-selectin but did not express activated CD11b. In exploring the effect of aspirin in 
sensitizing cancer cells to TRAIL mediated apoptosis, it was found that upon treating 
colon cancer cell line Colo205 with 1mM aspirin for 18 hours, multiple inhibitors of 
apoptosis were downregulated. Results suggest involvement of multiple proteins 
simultaneously in regulating apoptosis. 
KEYWORDS: metastasis, cell rolling, TRAIL, selectin 
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3.1 Introduction 
The formation of metastatic epithelial tumors involves a series of distinct, but 
related steps that shift the tumor cells from the primary tumor to a distal location. In 
the first step of the metastatic cascade, the cancer cell detaches from the primary 
tumor. Following detachment, they interact with the surrounding tissue, undergo 
epithelial-to-mesenchymal transition (EMT) and finally enter a nearby blood or lymph 
vessel (Pantel and Brakenhoff 2004; Royston and Jackson 2009; Vernon and LaBonne 
2004). Once in circulation, the cancer cells must evade the immune system and 
survive the stresses in circulation (MacDonald et al. 2002). Cancer cells can interact 
with the endothelium via selectins, in a manner similar to the leukocytes in the 
inflammatory cascade, and eventually come to rest where they may transmigrate (Gout 
et al. 2008; Krause and Turner 1999; Lafrenie et al. 1993). Circulating cancer cells 
may also transmigrate by forming aggregates with leukocytes either in blood or via 
secondary recruitment from a previously attached leukocyte (Geng et al. 2010; 
Slattery et al. 2005). Following transmigration, cells undergo the reverse process of 
mesenchymal to epithelial transition (MET) to survive in the new environment. To 
form a secondary tumor all these steps must be successfully completed. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or APO-2L), 
a member of the tumor necrosis factor (TNF) receptor superfamily, is known to induce 
apoptosis in transformed cells while sparing non-cancerous cells (Ashkenazi 2002; 
Ashkenazi and Dixit 1998; Griffith and Lynch 1998). TRAIL is known to bind to five 
different receptors, two of which are the death receptors (DR4 or TRAIL-R1 and DR5 
or TRAIL-R2) and two are decoy receptors (DcR1 or TRAIL-R3 and DcR2 or 
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TRAIL-R4) which are highly homologous to the death receptors but are incapable of 
inducing apoptosis due to the absence of the cytoplasmic death domain or a truncated 
death domain, respectively (Degli-Esposti et al. 1997a; Degli-Esposti et al. 1997b; 
Walczak et al. 1997). The fifth receptor, OPG binds TRAIL with very low affinity 
(Truneh et al. 2000).   
Non-steroidal anti-inflammatory drugs (NSAID) such as aspirin or 2-
acetoxybenzoic acid (ASA) have been implicated in reducing the occurrence of cancer 
(Giovannucci 1999; Williams et al. 1997). Inhibition in the growth of chemically-
induced bowel tumors was observed when rats were treated with NSAIDs (Kudo et al. 
1980).  Epidemiological studies involving the use of aspirin have shown a reduction in 
the occurrence of colorectal cancer (Kune et al. 2007). In particular, randomized trials 
with aspirin and salicylates have been shown to be particularly effective in reducing 
the probability of developing colorectal carcinoma (Elwood et al. 2009). In a separate 
study, pretreatment with aspirin was shown to sensitize prostate and colon cancer cells 
to TRAIL induced apoptosis (Kim et al. 2005; Yoo and Lee 2007). The sensitization 
shown by Kim et al. and Yoo et al. was attributed to downregulation of either Bcl-2 or 
survivin.  
In Chapter 2, I have demonstrated proof-of-concept of a device that can 
capture leukemic cancer cells from circulation and kill them. A schematic of the 
mechanism is shown in Figure 3.1A. In this study, I extend the use of the device as an 
adjunct therapy in which colon carcinoma cells are pretreated with aspirin and then 
perfused through the microtube device. Later in the study, the effect of aspirin 
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treatment on Colo205 cells were explored using a human apoptosis array detecting 
multiple proteins involved in apoptosis.  
Selectins are believed to be signaling molecules in addition to being adhesive 
molecules (Lee et al. 2007). In addition L-selectin is known to interact with E-selectin 
causing L-selectin crosslinking and subsequently activation (McEver et al. 1995). 
Activating PMNs may lead to accumulation of PMNs in the device thereby decreasing 
the available surface available for cancer cells to bind and possibly lead to leukopenia. 
Alternately, loss of L-selectin may lead to a suppressed immune surveillance. To this 
end, response of PMNs to express activated CD11b and loss of L-selectin by rolling 
over the combined surfaces was evaluated.  
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3.2 Materials and Methods 
3.2.1 Reagents and antibodies 
Human serum albumin (HSA), bovine serum albumin (BSA), Accutase™, 
HEPES, EDTA, acetylsalicylic acid (ASA), dimethyl sulfoxide (DMSO) and calcium 
carbonate were all obtained from Sigma-Aldrich (St Louis, MO). RPMI 1640 cell 
culture media, fetal bovine serum (FBS), Hank’s balanced salt solution (HBSS) and 
phosphate buffered saline (PBS) were all obtained from Invitrogen (Grand Island, NY). 
His-tagged recombinant human TRAIL (rhTRAIL), recombinant human E-selectin-
IgG chimera (rhE-selectin), human apoptosis antibody array and TACS Annexin-V 
FITC Apoptosis Detection Kit were purchased from R&D Systems (Minneapolis, 
MN). Protein-G and anti-His tag antibody were purchased from EMD Biosciences 
(San Diego, CA).  PBS based enzyme-free cell dissociation media was purchased from 
Millipore (Billerica, MA). 
3.2.2 Cell lines and cell culture 
Colon cancer cell line Colo205 (ATCC number CCL-222) was obtained from 
ATCC (Manassas, VA). These cells were cultured in RPMI 1640 supplemented with 
2mM L-Glutamine, 25mM HEPES, 10% v/v FBS and 100 U/mL PenStrep (complete 
media) under humidified conditions at 37˚C and 5% CO2. Cells were maintained so 
that 90% confluence was not exceeded.  
3.2.3 Preparation of immobilized protein surfaces 
Recombinant human E-selectin-IgG was dissolved in PBS to a final 
concentration of 100 !g/mL. In addition, stock solutions of TRAIL, protein-G and 
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anti-His tag antibody in PBS were prepared at 20 !g/mL, 100 !g/mL and 200 !g/mL 
respectively. Aliquots of the stock solutions were stored at –20 ºC and used as needed 
within 60 days. The surface was first incubated with 10 !g/mL protein-G solution for 
1.5 hours, followed by a 2 hour incubation with E-selectin chimera (2 !g/mL) or a 
combination of E-selectin chimera and anti-His tag antibody  (2 !g/mL and 10 !g/mL 
respectively), and then the surface was incubated with 20 !g/mL TRAIL solution. 
Each incubation step was followed with three washes with PBS. All incubations were 
conducted at room temperature and successful immobilization was confirmed by 
immunofluorescence. 
3.2.4 Cell preparation for rolling experiments 
Colo205 cells were treated with an enzyme-free cell dissociation media as per 
the manufacturer’s instructions. Briefly, 5 mL of enzyme free cell dissociation media 
was added to a 10 cm petri-dish and incubated for 5 minutes. Complete media (5mL) 
was added and cells were harvested. The cells were washed twice with 1X PBS at 
200xg in an Allegra X-22 refrigerated centrifuge at 4˚C and resuspended in the flow 
buffer at a concentration of 2 x 106 cells/mL. The flow buffer consisted of HBSS 
without Ca2+ and Mg2+ supplemented with 0.5% w/v HSA, 10mM HEPES and 2mM 
Ca2+. For all experiments, at least 90% viability of cells was confirmed by trypan-blue 
exclusion dye. 
3.2.5 Aspirin Treatment 
Aspirin (ASA) was dissolved in DMSO to a final concentration of 1 mM. Cells 
were cultured for 1 day before treating them with 1 mM ASA for 18 h at 37˚C and 5% 
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CO2. After ASA incubation, cells were harvested and washed twice in 1X PBS before 
being resuspending in flow buffer. 
To shed light on the underlying mechanisms that might be responsible for 
sensitizing the colorectal cancer cell line Colo205 to TRAIL following treatment with 
aspirin, Colo205 cells were treated with 1mM aspirin for 18 h. Cells were plated a day 
prior to treatment with aspirin to ensure growth in the linear phase of cell growth. Post 
treatment, cells were collected using enzyme-free cell dissociation media, washed and 
lysed to extract total protein. 400 µg/mL of total protein was allowed to incubate over 
a human apoptosis protein array from R&D systems pre-conjugated with appropriate 
capture antibodies to detect 48 proteins involved in apoptosis. After incubation, the 
membranes were washed and treated with horseradish peroxidase for 7 minutes. 
Relative expression levels of various pro-  and anti-apoptotic proteins were obtained 
from images taken on a Fuji Imaging system.   
3.2.6 Rolling experiments  
Micro-Renathane tubing, 300 !m internal diameter was obtained from 
Braintree Scientific (Braintree, MA), cut into 50 cm long segments and secured to the 
stage of the Olympus IX81 motorized inverted research microscope (Olympus 
America Inc, Melville, NY) after surface functionalization. The microscope was 
equipped with a CCD camera (Model No: KP-M1AN, Hitachi, Japan) connected to 
either a S-VHS videocassette recorder (Model No: SVO-9500MD2, Sony Electronics, 
Park Ridge, NJ) or a DVD recorder (Model No: DVO-1000MD, Sony Electronics, 
Park Ridge, NJ) to record video for offline analysis. A syringe pump (KDS 230, IITC 
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Life Science, Woodland Hills, CA) was used to control the flow rate of the cell 
suspension. Cells were loaded on the surface at a shear stress of 0.5-1 dyne/cm2 for 3 
min prior to each flow experiment. Microtube flow experiments were performed at 2.5 
dynes/cm2, for a period of 1 – 2  h. After flow, cells were separated into two fractions, 
“cells on surface” – cells that were rolling on or remained on the surface at the end of 
the experiment and “cells in flow” – cells that were collected into the syringe.  
The cells on the surface were harvested using 5mM EDTA and air embolism at 
10 dyne/cm2. These cells were then cultured for 16-18 hours and analyzed by 
Annexin-V assay. E-selectin and His-tag antibody (without TRAIL) functionalized 
surfaces were used as negative controls. 
3.2.7 PMN extraction 
Peripheral blood was collected from healthy adults after informed consent. 
PMNs were separated using 1-Step Polymorph™ (Accurate Chemicals) density 
gradient centrifugation. Briefly, 3mL of whole blood was carefully layered over 3mL 
of Polymorph. Cells were centrifuged at 480g for 50 min and the layer corresponding 
to PMN was extracted and washed in HBSS without Ca2+. RBCs were lysed using 1:6 
PBS. These cells were then centrifuged and resuspended in HBSS with Ca2+ for flow 
experiments.  
Rolling experiments as described earlier were performed. After the rolling 
experiment, cells were collected by perfusing Ca2+ free HBSS. Cells collected were 
then washed and fixed in 4% paraformaldehyde and labeled for total L-selectin and 
active CD11b on the cell surface using anti-human CD62L antibody and anti-human 
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CD11b antibody (both from BD Biosciences), respectively. Labeled cells were 
analyzed by flow cytometry. As positive control, PMNs were activated by treating 
PMNs with 100 !M interleukin-8 (IL-8).  
3.2.8 Data analysis 
“Rolling” cells were defined as those observed to translate in the direction of 
flow with an average velocity less than 50% of the calculated hydrodynamic free-
stream velocity. Rolling flux was determined by counting the number of cells crossing 
a line drawn in the field of view perpendicular to the flow direction, over a period of 1 
min. 
 Cells were analyzed for death and the mode of death by the Annexin-V 
apoptosis assay on an Accuri C6 flow cytometer. Manufacturer instructions were 
followed to prepare samples for flow cytometry. Briefly, Annexin-V is an 
anticoagulant that binds to negatively charged phospholipids. Flipping of 
phosphatidylserine (PS) in the cell membrane to the extracellular side (enabling 
Annexin-V to bind to PS) is considered an early event in apoptosis and is considered 
important for macrophage recognition of apoptotic cells. Cells that label for propidium 
iodide (PI), a DNA stain, possess a compromised cell membrane. Based on the dye 
taken up by cells, they are classified into four categories: viable cells (negative for 
Annexin-V and PI), early apoptotic cells (positive for Annexin-V only), late apoptotic 
cells (positive for Annexin-V and PI) and necrotic cells (positive for PI only). 
Where appropriate, the student’s t-test and one-way ANOVA with Tukey post 
test to compare all means were employed at a significance level of ! = 0.05. All 
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statistical analyses were performed using GraphPad Prism 5.0c for Mac OS X 
GraphPad Software, San Diego, CA USA (www.graphpad.com). 
  
 90 
3.3 Results 
3.3.1 Colon cancer cells exhibit shear-dependent rolling on E-selectin 
Colo205 cells were perfused through microtubes functionalized with rhE-
selectin at a shear stress range of 1 – 10 dyn/cm2. The surface density of E-selectin 
was varied by incubating the tube with different concentrations of E-selectin solution 
(0.1 – 10 µg/mL) at room temperature (RT). Figure 3.1B and 3.1C summarize the 
results from rolling experiments. Rolling was observed at 1 µg/mL and 2 µg/mL 
incubation concentrations of E-selectin. Adhesive interactions were observed only at 1 
dyn/cm2 for 0.1 µg/mL E-selectin. At higher shear stresses no adhesive interactions 
were observed. At higher concentrations of E-selectin (10 µg/mL and higher) firm 
arrest was seen with rolling velocities approaching zero even at the higher shear 
stresses. Extremely slow rolling was observed at 5 µg/mL E-selectin however, cells 
recovered had lower viability. The results from these experiments suggest that 2 
µg/mL of E-selectin allows stable rolling of Colo205 cells with relatively slow rolling 
velocities and a maximum rolling flux at a shear stress of 2 dyn/cm2 (Figure 3.1B, C). 
With increasing stress (>3 dyn/cm2), a decrease in the number of viable cells post 
rolling was observed (data not shown).   
3.3.2 Microtube flow device coated with TRAIL and E-selectin is able to capture 
colorectal cancer cells and induce apoptosis in a time-dependent manner. 
As a model of metastatic tumor cells, the colon cancer cell line Colo205 was 
used. Cells once harvested and washed were counted and resuspended in flow buffer 
at a concentration of 106 cells/mL and perfused through the microtube device as 
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described in the Materials and Methods section. After the flow experiments, cells were 
harvested and cultured in complete media for 18 h and later analyzed by the Annexin-
V assay. 
When cells were perfused over the functionalized surfaces for 1 h and analyzed, 
the difference in viability was observed to be around 13% between the cells that were 
harvested from the control surface of E-selectin + His tag Ab versus the TRAIL + E-
selectin (Figure 3.2A, C). A difference in viability between cells in culture and cells 
that rolled over the control surfaces is observed (Figure 3.2E). This difference may be 
due to the fluid force exerted on the cells over extended duration. Epithelial cells do 
not experience constant fluid force and when exposed to such forces the cells may die. 
It was expected that the kill rate could be significantly increased by extending 
the cell perfusion time to 2 h, still within the realistic contact time achievable under 
physiological conditions (Rana et al. 2009; Wojciechowski et al. 2008). To test my 
hypothesis, cells were prepared and perfused over the functionalized surfaces for 2 h. 
A 42% difference in the percentage of viable cells between the control surface lacking 
TRAIL and the two receptor surface of TRAIL + E-selectin was observed (Figure 
3.2B, C). By doubling the interaction time, an approximate threefold difference in kill 
rate was observed (Figure 3.2D).   
Taken together, the device is capable of capturing colon cancer cells from flow 
and killing them. As seen in figure 3.2, the mode of death is via apoptosis due to 
interaction of cancer cells with TRAIL. 
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3.3.3 Rolling on E-selectin alone does not activate integrins on PMNs. 
In addition to serving as adhesion molecules, selectins have also been shown to 
induce intracellular signals (Lee et al. 2007). Once activated, the PMNs may adhere to 
the surface thus saturating the surface and preventing the interaction of cancer cells 
with surface of the device rendering it ineffective. To investigate activation of PMNs 
while flowing through the device, PMNs isolated from peripheral blood were isolated 
as described in the Methods and Materials – PMN isolation – section.  
There was no statistical difference in the activated CD11b between cells 
collected from BSA-coated tubes and TRAIL + E-selectin tubes, while over 90% 
active CD11b when cells were treated with IL-8 (Figure 3.3A, C).  In the case of total 
L-selectin expressed by PMNs, a decrease in surface expression was observed (Figure 
3.3B, C).  While loss of L-selectin is considered an initial step in activation, loss of L-
selectin reduces the probability of PMNs to interact with the endothelium downstream, 
potentially compromising the immune surveillance function of leukocytes. 
3.3.4 Pretreatment with 1 mM aspirin increases TRAIL kill rate 
Aspirin has been shown to be effective in reducing the occurrence of colorectal 
cancer. To test the effect of aspirin mediated sensitization of colon cancer cells on the 
TRAIL-coated device, Colo205 cells were pretreated with 1 mM aspirin for 18 h in 
complete media at culture conditions. Cells were washed and either analyzed for 
apoptosis or perfused through the flow device as described earlier. Treating the 
colorectal cancer cell line Colo205 with 1 mM aspirin decreased the viability by about 
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3% when compared to the sham treatment without aspirin (Figure 3.4B top row). Cell 
death caused by aspirin treatment alone was not significant. 
When cells pretreated with 1 mM aspirin were perfused through the microtube 
flow device for 1 h and analyzed 18 h later for apoptosis by the annexin-V assay, an 
average difference in viability of 44.32 ± 8.64 %  was observed between the control 
surface of E-selectin (no TRAIL) and the combined surface of TRAIL + E-selectin 
(Figure 3.4A). Kill rate is defined as the difference in the number of viable cells 
between the control surface and the combined TRAIL + E-selectin surface. Kill rate of 
cells perfused through the microtube following aspirin pretreatment was found to be 
similar to perfusing untreated cells over the combined surface for 2 h (Figure 3.4C), 
while perfusing untreated cells for 1 h had a kill rate of about 17%. 
Aspirin treatment followed by 2 h perfusion over the combined surface was 
expected to further increase the kill rate as was seen with untreated cells. To test this 
hypothesis, aspirin-treated cells were collected after 2 h perfusion over both the 
control surface (without TRAIL) and the combined TRAIL + E-selectin surfaces and 
cultured for 24 h. Most cells collected from the combined surface had disintegrated in 
about 24 h and performing the annexin-V assay was not possible. Consequently, ten 
thousand ungated events were recorded on the flow cytometer for each sample. Based 
on the untreated, unrolled Colo205 a gate was set to denote viable cells. This gate was 
replicated for all samples and the total number of events within the gate was calculated 
(Figure 3.5E). Figure 3.5A is a plot of the number of events within the gate for each 
sample and representative flow cytometry histograms with counts and representative 
 94 
gating strategy are shown in Figure 3.5B. An 18% decrease in the cell count is seen 
between unrolled and cells that rolled over the control surface. This decrease in 
viability is due to the effects of fluid forces acting on the cells. However, when the 
control TRAIL-free surface is compared to the combined surface, almost 76.50% 
decrease is seen in the number of gated events.  
In a separate experiment, cells after the flow experiment were harvested and 
seeded at 100,000 cells/mL in multiwell plates. These cells were allowed to grow for 
three days in complete media and culture conditions and counted at day 3 using a 
hemocytometer. A 96% difference in the number of cells between the cells obtained 
from the control surface and the cells obtained form the combined TRAIL and E-
selectin surfaces (Figure 3.5C). Representative micrographs at days 3 are shown in 
Figure 3.5D. 
3.3.5 Aspirin treatment affects multiple inhibitors of apoptosis 
To shed light on the underlying mechanisms that might be responsible for 
sensitizing the colorectal cancer cell line Colo205 to TRAIL following treatment with 
aspirin, total protein extracted from cell lysates was used as described in materials and 
methods – aspirin treatment section. 
The array indicated a general decrease in pro-survival proteins. While Bcl-2 
downregulation was the largest, HSP27, PON2 and cIAP-2 showed a difference of 
greater than fourfold in the relative luminescence intensity (Figure 3.6). Colo205 
treated with 0.1 mM aspirin alone for 18 h showed no significant difference in the 
expression levels of inhibitors of apoptosis (data not shown). To identify the major 
 95 
proteins responsible for aspirin mediated sensitization of Colo205 cells to TRAIL 5 
mM aspirin was tested, however 5 mM lead to decreased pH of the media, making it 
unsuitable for cell growth. 
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3.4 Discussion 
In the present study, I build upon results presented in Chapter 2, by extending 
the method of capturing circulating colon cancer cells on a combined TRAIL + E-
selectin surface to cells of epithelial origin. Based on measurements of rolling 
velocities (Figure 3.1B), sustaining longer rolling contact was possible. It was 
determined that increasing the contact time from 1 to 2 h increases the kill rate by 
almost three-fold. This is consistent with previous prediction (Chapter 2) wherein it 
was predicted that longer duration (potentially with recirculation) would increase the 
probability of capture and subsequent increase in kill rate.  
Aspirin has been shown to reduce the occurrence of cancer (Elwood et al. 
2009; Gann et al. 1993; Peto et al. 1988; Williams et al. 1997), however dosage for 
cancer preventive action is still debated. In a 5-year follow-up study in the United 
States, 22,071 men were randomized to a daily dosage of 325 mg of aspirin or placebo, 
researchers reported that the relative risk of developing colorectal cancer in men 
receiving aspirin every day was lower compared to control (Gann et al. 1993). Similar 
cancer preventive effect was seen with breast and prostate cancers (Chan et al. 2007; 
Jacobs et al. 2005; Ruffin et al. 1997; Terry et al. 2004). Aspirin has been shown to 
sensitize cancer cells to TRAIL-mediated apoptosis by downregulating inhibitors of 
apoptosis (Kim et al. 2005; Yoo and Lee 2007). Kim and coworkers found that with 
LNCaP cells aspirin treatment downregulates Bcl-2, thereby sensitizing cells to 
TRAIL while Yoo and coworkers found that the sensitization is a result of 
downregulation of survivin (Kim et al. 2005; Yoo and Lee 2007). Both studies used 
LNCaP have found different results which suggest that there may be more than a 
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single protein/gene that may be responsible for the overall sensitization of cancer cells 
to TRAIL mediated apoptosis; consistent with the results of this study (Figure 3.6). 
The regulation of the apoptosis signal is a complex process involving multiple proteins 
(Figure 1.4). A more detailed discussion on this topic and the proteins involved in 
regulating this process can be found in section 1.3.1.  
Cancer cells have been shown to interact with the endothelial lining of the 
vasculature by a variety of adhesion molecules as initial steps in extravasation (Goetz 
et al. 1996; Kim et al. 1999; Orr and Wang 2001; Orr et al. 2000).  It is believed that 
this contact with the endothelium initiates a cascade of activation events, similar to 
that of PMN recruitment during inflammation, and ultimately leads to the 
development of a metastatic tumor (Orr et al. 2000). King laboratory and others have 
shown that cancer cells exhibit selectin-dependent rolling under flow (Burdick et al. 
2003; Hanley et al. 2006; Konstantopoulos and Thomas 2009; McCarty et al. 2000; 
Rana et al. 2009). In particular, E-selectin has been implicated as an important selectin 
molecule for colorectal cancer interactions with the endothelium (Tremblay et al. 
2008; Woodward 2008; Zaifert and Cohen 1993).  Figure 1.2B lists some of the 
interactions between selectins and their ligands. In addition, this study demonstrates 
that Colo205 cells interact with surfaces functionalized with E-selectin, exhibiting a 
shear dependent rolling velocity (Figure 3.1B, C) 
L-selectin expressed by human PMNs is decorated with sialylated, fucosylated 
glycans suggesting the interaction between circulating leukocytes and the E-selectin 
(McEver et al. 1995) on the functionalized device. To this extent, PMNs isolated from 
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peripheral blood were perfused over the functionalized microtube. As noted in figure 
3.3, there was a substantial shedding of L-selectin from the surface of the PMNs 
making them less sticky downstream, however there was no negligible increase in 
activated surface bound CD11b. While L-selectin shedding makes the leukocytes less 
sticky, the absence of L-selectin may reduce the ability of leukocytes to perform their 
surveillance. However, the presence of other adhesion molecules on the PMN surface 
would still allow adhesion of the PMNs on activated endothelium. 
With increasing time, a small increase in killing of Colo205 cells is seen on the 
control surface containing E-selectin when compared to cells in culture. This kill can 
be attributed to lack of attachment necessary for the growth of epithelial cells. 
Colo205 cells, like other cancers of epithelial origin, also require attachment to matrix. 
When epithelial cells are prevented from attaching, they undergo anoikis. 
From a mechanism point of view a lubrication layer close to the surface is 
created in flow. This layer retards the sedimentation of cells thereby decreasing the 
overall capture efficiency. In addition, the available surface area for molecules to be 
adsorbed on is fixed based on the geometry of the tube. Previous efforts by the King 
lab have shown ways to increase the available surface area by changing the nanoscale 
topography of the microtube (Han et al. 2010; Hughes and King 2010). In particular, 
naturally occurring silica nanotubes have been used to allow capturing cells faster by 
overcoming the lubrication layer and help retain more cells on the surface. The use of 
silica nanotubes may help improve capture and subsequent killing of cancer cells. 
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The described microtube may be tailored to specific cancer types by 
functionalizing the surface with small peptides or other protein molecules that may be 
more selective at capturing cells. Small molecule replacements would be more stable 
thereby increasing the shelf life of the device. In addition, the molecules may be 
customized to capture specific cell types. Cells captured in this manner may then be 
reprogrammed or neutralized before being released into the circulation. The same 
technology (with modifications) may be utilized to capture and enrich rare cells from 
peripheral circulation, which may then be used for clinical research.  
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3.5 Conclusion 
I have previously demonstrated proof-of-concept for an implantable device that 
is capable of capturing cancer cells from flow and induce apoptosis in the captured 
cells. In this study, I further that work by demonstrating the feasibility to capture cells 
of epithelial origin and induce apoptosis. This study verifies the previous hypothesis 
of rolling delivery being time-dependent, as demonstrated by the 2 h and 1 h rolling 
kill rates. In addition, I have demonstrated a scenario in which the device may be used 
as an adjuvant therapy when treated with aspirin. Low dosage of aspirin by itself does 
not kill cancer cells, but significantly sensitized them to TRAIL-mediated apoptosis as 
demonstrated by this study. In a single pass of 2 h through the device, over 90% of 
Colo205 cells pretreated with aspirin were killed. Until now, sensitization to TRAIL 
mediated apoptosis has been attributed to downregulation a single protein. However, 
my results show that multiple proteins may be involved in sensitizing cancer cells to 
TRAIL. Aspirin has shown effect in sensitizing cancer cells to TRAIL, however the 
mechanism for sensitization needs a more thorough study. The proposed device when 
used as an adjuvant therapy may significantly reduce metastatic load and potentially 
improve cancer treatments. 
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Figure 3.1 : Interaction of Colo205 with microtubes functionalized with E-selectin 
under physiological shear stress. (A) Schematic of two-receptor delivery system. 
(B) Rolling velocity and (C) rolling flux as a function of E-selectin concentration 
and wall shear stress.
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4.0 Abstract 
Metastasis remains the major cause of cancer related deaths. Tumor Necrosis 
Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) or Apo2L has shown 
promise as a therapeutic in the case of cancer treatment, however the small size of the 
protein limits the use of the protein due to the quick clearance times from the human 
body. As a result, higher amounts of TRAIL or antibodies against TRAIL receptors 
may be required to overcome the short residence time within the body. In order to 
address the clearance times and possibly aid in trimerization of TRAIL, in the current 
study proposes developing nanoscale liposomes bearing TRAIL and E-selectin that 
bind to circulating cancer cells and kill them. Using the colorectal cancer cell line 
Colo205, we have shown that the nanoscale lipids bind to cells under shear with high 
efficiency and kill over 50% of cells in two hours. When cancer cells were spiked in 
blood, a kill of over 90% was seen when compared to control lipids without TRAIL 
while no effect of the liposomes was seen on peripheral blood mononuclear cells 
under static conditions of culture with liposomes for 24 h and under conditions of 
uniform shear. 
 
KEYWORDS: TRAIL, liposomes, metastasis, selectin, cancer  
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4.1 Introduction 
For patients with cancer, the formation of metastatic tumors is often a poor 
prognostic indicator, with most cancer-related deaths being associated with formation 
of the secondary tumors. Once in blood, cancer cells are believed to interact with the 
endothelium in a manner similar to leukocytes (Orr et al. 2000). Upon contact with the 
endothelium, cancer cells exhibit a rolling behavior via transient bonds between 
selectins and their ligands and eventually transmigrate into the extravascular tissue 
where they may form secondary tumor (Chambers et al. 1995; Chambers et al. 2000; 
Chambers et al. 2001; MacDonald et al. 2002). Our laboratory and others have shown 
that cancer cells exhibit this selectin-dependent rolling behavior under flow (Burdick 
et al. 2003; Hanley et al. 2006; Konstantopoulos and Thomas 2009; McCarty et al. 
2000; Rana et al. 2009). In particular, E-selectin has been implicated as an important 
selectin molecule for colorectal cancer interactions with the endothelium (Tremblay et 
al. 2008; Woodward 2008; Zaifert and Cohen 1993). 
Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL), 
also known as CD253, is a 60 kD type II transmembrane protein, first identified based 
on its sequence homology to TNF and FasL (Pitti et al. 1996; Wiley et al. 1995). 
TRAIL is know to bind to five different receptors, two of which induce apoptosis via 
the caspase pathway and are known as the death receptors (DR4 or TRAIL-R1 and 
DR5 or TRAIL-R2)(Pan et al. 1997a; Pan et al. 1997b; Screaton et al. 1997; Walczak 
et al. 1997) and two decoy receptors (DcR1 or TRAIL-R3 and DcR2 or TRAIL-R4) 
that do not induce apoptosis due to a lack of cytoplasmic portion which is required to 
recruit the death domain (Degli-Esposti et al. 1997a; Degli-Esposti et al. 1997b; 
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Sheridan et al. 1997). The fifth receptor is a low affinity receptor OPG (Truneh et al. 
2000) that has a role in bone remodeling. Previous studies with TRAIL have shown 
that TRAIL exerts its cytotoxic effects in many different cancer cell lines. Unlike 
other members of the TNF family, TRAIL exerts its cytotoxic effects on transformed 
cells while mostly sparing non-cancerous cells (Ashkenazi 2002; Fricker 1999; Held 
and Schulze-Osthoff 2001; Plasilova et al. 2002). Recombinant soluble human TRAIL 
has been shown to induce apoptosis in several cancer cell lines and mouse xenografts 
(Ashkenazi et al. 1999; Gazitt 1999; Mitsiades et al. 2001; Oikonomou et al. 2007; 
Walczak et al. 1999; Yu et al. 2000). These qualities make TRAIL a promising 
candidate for cancer therapy. However, the small size of the molecule poses potential 
issues maintaining the required active concentration (Xiang et al. 2004).  
In a rabbit model of rheumatoid artheritis, researchers have demonstrated the 
efficacy of TRAIL bound liposomes (Martinez-Lostao et al. 2010). Martinez-Lostao et 
al. in their study found that when TRAIL bound liposomes were injected into the hind 
legs of rabbits, they were effective in alleviating artheritis related inflammation.   
While TRAIL has been shown to be effective, the half-life of the molecule is 
extremely small (~30 min). On the other hand, several cancer cells have over-
expressed selectin ligands (Chapter 1, Appendix II). In this study TRAIL and E-
selectin decorated nanoscale liposomes are used to target metastatic cancer cells. E-
selectin on the liposome allows binding of liposome to the cancer cell while TRAIL 
exerts its cytotoxic effect.    
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4.2 Materials and Methods 
4.2.1 Reagents and antibodies 
Human serum albumin (HSA), bovine serum albumin (BSA), Accutase™, 
HEPES, DMSO, NaCl, MgCl2, CaCO3 and chloroform (ACS grade with 0.5 – 1% 
ethanol added as stabilizer) were all obtained from Sigma-Aldrich (St Louis, MO). 
RPMI 1640 cell culture media, fetal bovine serum (FBS), Hank’s balanced salt 
solution (HBSS), Penicillin-streptomycin (PenStrep) and Dulbecco’s phosphate 
buffered saline (DPBS) were all obtained from Invitrogen (Grand Island, NY). His-
tagged recombinant human TRAIL (rhTRAIL), his-tagged recombinant human E-
selectin-IgG chimera (rhE-selectin) and TACS Annexin-V FITC Apoptosis Detection 
Kit were purchased from R&D Systems (Minneapolis, MN). PBS-based enzyme-free 
cell dissociation media was purchased from Millipore (Billerica, MA).  L-!-
lysophosphatidylcholine from egg (Egg PC), sphingomyelin from egg (Egg SM), 
ovine wool cholesterol (Chol), 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) (DOGS NTA-Ni) and 23-
(dipyrrometheneboron difluoride)-24-norcholesterol (Bdp-Chol, Ex/Em 490 nm/504 
nm) either dissolved in chloroform (Egg PC, Egg SM, Chol, DOGS NTA-Ni) or in 
powder form (Bdp-Chol) were purchased from Avanti Polar Lipids (Alabaster, AL). 
4.2.2 Cell lines and cell culture 
Colon cancer cell line Colo205 (ATCC number CCL-222) was obtained from 
ATCC (Manassas, VA). These cells were cultured in RPMI 1640 supplemented with 
2mM L-Glutamine, 25mM HEPES, 10% v/v FBS and 100 U/mL PenStrep (complete 
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media) under humidified conditions at 37˚C and 5% CO2. Cells maintained such that 
90% confluence was not exceeded. Cells were regularly tested for contamination and 
were not used past passage 45. 
Colo205 were gently harvested using enzyme-free cell dissociation media. 
Cells were washed twice with 1X DPBS at 200g in a refrigerated centrifuge. After 
washing, cells at a concentration of 106 cells/mL were resuspended in HBSS based 
resuspension buffer supplemented with 0.5% w/v HSA, 10 mM HEPES and 2 mM 
Ca2+.For all experiments, >95% viability was assessed by trypan blue exclusion dye. 
4.2.3 Preparation of nanoscale lipids 
Multilamellar liposomes, composed of egg L-!-lysophosphatidylcholine (Egg PC), 
egg sphingomyelin (Egg SM), ovine wool cholesterol (Chol), 1,2-dioleoyl-sn-glycero-
3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) (DOGS 
NTA-Ni) at weight ratios 60-50%:30%:10%:0-10% (Egg PC/Egg SM/Chol/DOGS 
NTA-Ni), were prepared by thin lipid film method (Huang and King 2009). DOGS-
NTA-Ni is a lipid conjugated to nickel-nitrilotriacetic acid (Ni-NTA) that allows 
attachment of his-tagged proteins to itself. Briefly, stock solutions of all lipids were 
prepared by dissolving powdered lipids in chloroform to produce a final concentration 
of 5 mg/mL Egg PC, 20 mg/mL Egg SM, 5 mg/mL Chol and 20 mg/mL DOGS-NTA-
Ni in glass containers and stored at -20°C. Appropriate volumes of the lipids were 
taken from the stock solution to make lipids with varying concentrations of DOGS 
NTA-Ni in a glass tube and gently dried under nitrogen. To ensure complete removal 
of chloroform, the lipids were left under vacuum for an additional 12 h. With 
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increasing amounts of DOGS NTA-Ni, the corresponding amount of Egg PC was 
decreased (Table 4.1). The lipid film was hydrated with a liposome buffer composed 
of 150 mM NaCl, 10 mM HEPES and 1 mM MgCl2 dissolved in nuclease-free water 
to create multilamellar liposomes. The resulting multilamellar liposomes were sized 
by repeated thawing and freezing, and then subjected to 15 extrusion cycles at 60ºC 
through two different pore size (200 and 100 nm) polycarbonate membranes 
(Nucleopore, Whatman, NJ, USA) to produce unilamellar nanoscale liposomes 
(Figure 4.1).  
Recombinant human E-selectin-IgG and TRAIL were dissolved in nuclease-
free sterile water to a final concentration of 1mg/mL and 100 !g/mL. Aliquots of 
stock solutions were stored at –20 ºC and used as needed within 60 days. The freshly 
prepared nanoscale liposomes were then incubated with rhTRAIL (final concentration 
71.43 nM) and rhE-selectin Fc Chimera (250 nM final concentration) for 30 min at 
37ºC and then overnight at 4ºC to ensure maximum binding of the proteins via the 
interaction between his tag and Ni-NTA. To remove unbound TRAIL and E-selectin, 
liposomes were diluted 1:3 with liposome buffer and subjected to ultracentrifugation 
at 100,000g for 3 h  at 4ºC. The supernatant with unbound TRAIL and E-selectin was 
carefully removed and collected for further evaluation and the liposomes were 
gradually resuspended in the liposome buffer to make the conjugated nanoscale 
liposomes. A similar procedure was followed to make fluorescent conjugated 
liposomes by replacing ovine wool cholesterol with 23-(dipyrrometheneboron 
difluoride)-24-norcholesterol. 
Freshly prepared nanoscale liposomes were diluted in the liposome buffer, and 
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the mean particle diameter and surface charge (zeta potential) were measured by 
dynamic light scattering using the Malvern Zetasizer nano ZS (Malvern Instruments 
Ltd., Worcestershire, UK), according to the manufacturers’ protocols. Conjugated 
liposomes were measured to be 107.8±10.3 nm and have a zeta potential of -5.7±4.6 
mV.  
4.2.4 Static experiments 
Colo205 cells were seeded in multiwell plates at a seeding density of 300,000 
cells/mL 1 day prior to experimentation to ensure that the cells were in the linear 
phase of the growth cycle. Media was changed prior to experimentation. Either the 
supernatant from ultracentrifugation or 5 !L of conjugated and purified liposomes 
were added to cells. The cells were maintained in culture conditions with the 
supernatant or nanoscale lipids for 24 h and later analyzed by annexin-V assay to 
quantify the proportion of viable cells.  
4.2.5 Mononuclear Cell (MNC) Isolation 
All human subject protocols were approved by the Institutional Review Board 
for Human Participants of Cornell University. Peripheral blood was collected from 
healthy, willing donors after informed consent into vacutainer tubes containing 
heparin and allowed to equilibrate at room temperature (RT) before use. Three mL of 
blood diluted with resuspension buffer was carefully layered over 3 mL of Ficoll-
Paque PLUS™ (GE Healthcare, Piscataway, NJ) and centrifuged at 480g for 50 min at 
RT. Buffy coat containing MNCs was collected and washed twice with resuspension 
buffer. Cells collected were either resuspended in resuspension buffer and used for 
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shearing experiments or resuspended in complete media for static experiments. For 
shearing experiments, 490 !L of cell suspension (at 106 cells/mL) mixed with 10 !L 
of nanoscale lipid particles was immediately added to the cone-and-plate viscometer 
as described in the next section.  
4.2.6 Uniform shear flow experiments 
To simulate shear stress conditions of blood flow, cancer cells were subjected 
to uniform shear in a cone-and-plate viscometer. Cancer cells seeded a day prior to the 
experiment day were gently detached from the surface using a PBS-based enzyme-free 
cell detachment solution. Cells were then washed twice in 1X DPBS and resuspended 
in resuspension buffer at a concentration of 1 x 106 cells/mL. Ten !L of lipids was 
added to 490 !L of cell suspension (at 106 cells/mL) and immediately added to the 
cone-and-plate viscometer. Shear rate was set to 75 s-1 for 2 h. After 2 h, the cells were 
removed and washed twice in resuspension buffer at 200g for 5 min. Finally; the cells 
were resuspended in complete media and cultured for 24 h. In the case of fluorescent 
lipid, an aliquot was taken for visual inspection on an inverted microscope (Olympus 
America Inc, Melville, NY) equipped with fluorescence and an intensified CCD 
digital camera (Cooke Corporation, Romulus, MI) to record images. The remaining 
cells were further divided to analyze via flow cytometry and viability assays.  
For spiking experiments, peripheral blood was collected into vacutainer tubes 
containing heparin and allowed to equilibrate to RT before use. Colo205 cells were 
prepared as described above. Cells were suspended at a concentration of 106 cells/mL 
in resuspension buffer. One milliliter each of whole blood and resuspension-buffer 
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containing cancer cells (at 106 cells/mL) were mixed. Ten !L of lipid was then added 
to 490 !L of blood spiked with resuspension buffer containing Colo205 cells and 
immediately added to the cone-and-plate viscometer previously coated with 5% BSA. 
Spiked blood was subjected to a uniform shear rate of 188 s-1 for 2 h.  
After shearing, 370 !L was recovered from the device and carefully layered 
over 1.5 mL of Ficoll-Paque PLUS™ and centrifuged at 480g for 50 min at RT. The 
buffy coat containing the MNC and cancer cells was recovered and washed twice in 
resuspension buffer to remove any unbound liposome and the separation media. Cells 
recovered were collected and cultured for 24 hours and analyzed via flow cytometry. 
4.2.7 Data analysis 
 Cells were analyzed for death and the mode of death by the Annexin-V 
apoptosis assay on an Accuri C6 flow cytometer. Samples were prepared for the 
annexin-V assay as per the manufacturer’s instructions. Briefly, based on the dye 
taken up by cells, the cells are classified into four categories: viable cells (negative for 
Annexin-V and PI), early apoptotic cells (positive for Annexin-V only), late apoptotic 
cells (positive for Annexin-V and PI) and necrotic cells (positive for PI only).  
In the case of spiking experiments, unlabeled samples of pure cancer cells and 
Ficoll-Paque PLUS™ separated buffy coat were run ungated until 10,000 - 50,000 
total events were acquired. A gate was then set based on the viable 
unsheared/untreated pure cancer cell control. This gate was later used to obtain the 
total number of events for cells collected after the Ficoll-Paque PLUS™ separation. It 
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was verified over 95% of the cells spiked in blood are retrieved after the Ficoll-Paque 
PLUS™ separation. 
Where appropriate, student’s t-test and one-way ANOVA with Tukey post test 
comparing all means was employed at a significance level of ! = 0.05. All statistical 
analyses were performed using GraphPad Prism 5.0c for Mac OS X GraphPad 
Software, (San Diego, CA USA, www.graphpad.com.) 
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4.3 Results 
4.3.1 Increasing the amount of NTA increases the amount of TRAIL bound to the 
lipids 
Liposomes with varying concentrations of DOGS NTA-Ni (Table 4.1) were 
prepared as described in the Materials and Methods section. Briefly, lipids conjugated 
with TRAIL alone were prepared and subjected to ultracentrifugation to remove 
unbound TRAIL. Ten !L of the concentrated supernatant was added to 490 !L of cells 
at a concentration of 300,000 cells/mL in complete media and cultured for 24 h. The 
cells were then analyzed by flow cytometry. Results indicate that increasing the 
amount of DOGS NTA-Ni increased the viability of cancer cells when treated with the 
supernatant (Figure 4.2A). While a maximum kill was observed from cells treated 
with the supernatant from 0% NTA (Figure 4.2B), a decrease in the kill rate is seen 
when cells were treated with the supernatant from 1% NTA (Figure 4.2C) and a 
further decrease in the kill rate is seen with the supernatant from 5% NTA (Figure 
4.2D). No significant increase is seen in the kill rate when cells were treated with 
supernatant of 10% NTA (Figure 4.21E). This suggests that DOGS NTA-Ni binds the 
His tagged TRAIL and 5% NTA is sufficient to bind most available TRAIL with 
viability comparable to culture conditions (Figure 4.2F). 
4.3.2 10% NTA is the optimum concentration for TRAIL-bearing nanoscale lipids 
To test the ability of TRAIL bound liposomes to kill Colo205 cells, 5 !L of 
liposomes were added to 495 !L of a 300,000 cells/mL suspension of Colo205. Cells 
were cultured with the liposomes for 24 h and then analyzed via flow cytometer. 
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Increasing the amount of DOGS NTA-Ni in the nanoscale liposomes results in 
increased kill rate. Since TRAIL mediated apoptosis is concentration dependent, 
decrease in viability suggest increased TRAIL binding (Figure 4.3A). When cells were 
treated with 0% NTA lipids, an average of 90% viable cells was seen (Figure 4.3B), 
however, when the cells were treated with 1% NTA liposomes the viability dropped to 
about 55% (Figure 4.3C). Treating cells with 5% NTA liposomes further reduced the 
viability to around 50% (Figure 4.3D). No significant decrease in viability was seen 
when treating with 10% NTA liposomes, with viability reaching a plateau around 50% 
cell viability (Figure 4.3A,E). Consistent with the results from Figure 4.2 and taking 
into account that there will be E-selectin protein added, it was concluded that 10% 
DOGS NTA-Ni was determined to be the optimal concentration for the proposed 
application. 
4.3.3 Shearing Colo205 cells with nanoscale lipids kills over 50% cells in 2 h, with 
over 95% cells are bound to liposomes. 
To test the efficacy of nanoscale liposomes to target blood-borne metastatic 
cells under flow, Colo205 cells suspended in resuspension buffer and lipids were 
subjected to uniform shearing conditions at a shear rate of 75 s-1 for 2 h. Cells were 
then washed twice in resuspension buffer to remove any unbound liposomes. The cells 
were cultured for 24 h prior to analysis by flow cytometry. Results indicate that naked 
liposomes (liposomes without TRAIL or E-selectin) and liposomes with E-selectin 
only did not have any killing effect on the cancer cells, while liposomes conjugated to 
TRAIL alone killed ~ 5% cells (Figure 4.4A, C, D, E). Liposomes conjugated with 
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TRAIL and E-selectin killed over 50% cells when compared to controls (Figure 4.4A, 
F).  
To quantify the degree of liposome binding to cells, fluorescent liposomes 
were sheared with the cancer cells for 2 h at a shear rate of 75 s-1. Cells were washed 
with resuspension buffer and analyzed via flow cytometry. Results indicate over 95% 
binding of liposomes to cancer cells subjected to shearing conditions (Figure 4.5A, B, 
F).  
4.3.4 E-selectin is essential to induce TRAIL mediated toxicity of liposomes in shear 
flow 
When liposomes with only TRAIL conjugated where placed under static 
conditions, the liposomes were capable of killing cancer cells (Figure 4.3A). However, 
when the same liposomes were subjected to shear they killed only ~ 5% of the cells in 
2 h (Figure 4.4A). When TRAIL and E-selectin were both conjugated to the liposomes, 
an increase in the kill rate was observed (Figure 4.4A, D, F). Liposomes with E-
selectin alone were not capable of killing cancer cells (Figure 4.4A). Taken together, 
these results indicate that both E-selectin and TRAIL are necessary for the liposomes 
to target and kill Colo205 cells.  
4.3.5 No detrimental effect of nanoscale liposomes is seen on peripheral blood 
MNCs 
MNCs express selectin ligands and as a result may interact with the liposomes 
thus potentially resulting in the undesirable effect of killing blood cells. MNCs were 
isolated from fresh peripheral blood by density gradient separation as described in the 
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Materials and Methods section. Isolated cells were divided into two groups: static and 
under flow. Each group was further subdivided into two groups: control and treated. 
The treated group was exposed to TRAIL + ES liposomes while the control group was 
exposed to naked liposomes. 
Briefly, 490 !L of MNCs resuspended in complete media was mixed with 10 
!L of the appropriate lipid. Cells were then cultured for 24 h with the liposomes. They 
were then analyzed for viability by the annexin-V assay. In the case of shearing 
experiments 490 !L of MNCs in resuspension buffer was mixed with 10 !L of the 
appropriate lipid. The mixture was then placed in a cone-and-plate viscometer and 
sheared at s shear rate of 75 s-1 for 2 h. Cells were collected, washed twice in 
resuspension buffer and cultured in complete media for 24 h. Cells were analyzed for 
viability by the annexin-V assay. We observed that although there is a small decrease 
in viability of MNCs when compared with control conditions, the difference is not 
statistically significant (Figure 4.5C, D, E).  
4.3.6 Over 90% cancer cell kill rate is observed when nanoscale lipid particles are 
sheared in blood 
To simulate conditions of metastasis through the bloodstream, Colo205 cells 
were spiked in diluted blood. 125,000 Colo205 cells in 1:1 (v/v) diluted blood were 
subjected to shear flow for 2 h in a cone-and-plate viscometer. Cells were recovered 
from the viscometer isolated with Ficoll-Paque PLUS™ density gradient. The buffy 
coat was recovered, washed and resuspended in media and cultured for 24 h. 
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Cells were washed after 24 h and analyzed via flow cytometry. To gate for the 
viable cells, 10,000 ungated events containing healthy Colo205 were processed. These 
events were then used to gate viable cancer cells. Then, the buffy coat corresponding 
to treatment with control liposomes containing E-selectin only and the liposomes with 
TRAIL and E-selectin were analyzed via flow cytometry. Fifty thousand ungated 
events were acquired for each case and the gate corresponding to healthy (culture 
condition) Colo205 cells was used to obtain the number of viable cells in the two 
samples. Our results indicate an over 90% difference in the number of cells when 
compared to control conditions (Figure 4.6A). Figure 4.6B shows representative flow 
cytometry histograms of this analysis. The gray shaded histogram corresponds to 
cancer cells from culture conditions that were not subjected to liposomes. The green 
histogram corresponds to the cells subjected to shear flow with E-selectin only 
liposomes while the red histogram was obtained from cell counts for cells sheared 
with TRAIL and E-selectin liposomes. It should be noted that the right shift in the 
peak is a result of the increase in cell size due to aggregates of cancer cells and MNCs 
mediated by liposomes or aggregates of liposomes bound to the cancer cell. In 
addition, there may be some aggregates of MNCs formed as a result of multiple cells 
binding to a single cell via its interaction with liposomes bound on the first cells. The 
resulting aggregates may be similar in size to cancer cells and may be counted as false 
positive. 
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4.4 Discussion 
TRAIL has shown be effective in killing several cancer cell lines while sparing 
non-cancerous cells (Ashkenazi et al. 1999; Walczak et al. 1999). Thus, TRAIL 
application displays a promising application for cancer therapy. To improve receptor 
oligomerization that is necessary to transmit the death signal, several-tagged versions 
of TRAIL have been created (Ganten et al. 2006; Pitti et al. 1996; Schneider 2000; 
Walczak et al. 1999). However, all tagged version exert some cytotoxicity to non-
cancerous cells (Koschny et al. 2007; Lawrence et al. 2001). Large quantities of 
untagged TRAIL may be required to inhibit tumor growth in vivo as most protein is 
cleared from the body within 5 h (Walczak et al. 1999). Consequently, targeted 
delivery methods may represent the best way to deliver TRAIL.  One such method 
uses adenoviral vector encoding human TRAIL (Griffith and Broghammer 2001). This 
method produces TRAIL locally and as a result may be effective in targeting cells in 
circulation. In addition, many tumors do not possess Coxsackie-adenovirus receptor, 
which is responsible for recognition and subsequent internalization of adenoviruses 
(Okegawa et al. 2000; Rauen et al. 2002). Another approach was to create TRAIL 
fusion protein (Bremer et al. 2004; Bremer et al. 2005). In their work, Bremer et al. 
created fusion proteins with TRAIL and the Fab fragments of antibody to target 
specifically the primary tumor. Liposomes being larger than proteins have a larger 
clearance time, thus improving circulation times. PEGylation of liposomes using lipids 
conjugated with PEG can further improve circulation time. In addition, E-selectin used 
would be useful in targeting circulating cancer cells expressing selectin ligands. Thus 
TRAIL and E-selectin decorated liposomes may be a better method to deliver TRAIL. 
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Activated NK cells present TRAIL, which is believed to be one of the 
mechanisms by which NK cells exert their cytotoxicity (Zamai et al. 1998). There are 
several studies performed in mice that demonstrate that NK cells are involved in 
eradication of tumor cells. (Hayakawa and Smyth 2006; Kaplan et al. 1998; Kim et al. 
2000; Shankaran et al. 2001; Wu and Lanier 2003). Correlative studies in humans 
have shown evidence for the role of NK cells in tumor surveillance (Imai et al. 2000). 
These results suggest an important role played by NK cells in cancer. Furthermore, 
researchers have shown that the infiltration of tumors with NK cells leads to a positive 
prognosis (Coca et al. 1997; Ishigami et al. 2000; Villegas et al. 2002). Despite the 
obvious benefits of NK cells in cancer surveillance, infiltration of NK cells into 
tumors has been shown to be poor; probably due to poor homing of NK cells 
(Albertsson et al. 2003).  Clinical trials in which IL-2 activated NK cells were 
introduced to patients with solid tumors and metastatic diseases have proved to be 
effective (Rosenberg et al. 1993). However, IL-2 is associated with acute toxicity 
represented by capillary leak syndrome (Fehniger et al. 2002). In addition, IL-2 
activated NK cells increase their sensitivity towards apoptosis when in contact with 
the endothelium, whereas IL-15 promotes NK survival and proliferation (Fehniger et 
al. 2002). Unfortunately, for IL-15 treatment to have any meaningful effect in vivo, 
extremely high dosages are required and alternate treatments are being explored 
(Kobayashi et al. 2005). Cretney et al. in their study showed that TRAIL-deficient 
mice have a higher propensity to form tumors, suggesting that TRAIL is an important 
molecule for defense against transformed cells (Cretney et al. 2002).  
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Based on the above literature it is believed that the nanoscale liposomes 
discussed in the presented work will be able to alleviate some of the above-mentioned 
problems. Since these lipids are synthetically prepared, they can be easily modified to 
target specific cancers based on their surface markers. This may lead to improved 
homing to the tumor microenvironment. In addition, the lipids can be decorated with 
polyethylene glycol (PEG) to become so-called “stealth liposomes” and evade 
mononuclear phagocytosis. PEGylation of liposomes will improve circulation time 
(Immordino et al. 2006).  
Clinical studies of leukemic patients who received NK cells in the course of 
allogeneic hematopoietic stem cell transplant shows increased survival rates and 
protection from relapse (Hsu et al. 2005). However, allogeneic transplants come with 
the risk of host-versus-graft disease while autologous transplants run the risk of 
reintroducing cancer cells. Our lab has demonstrated a selectin functionalized flow 
device capable of capturing and enriching CD34+ stem and progenitor cells from 
circulation for eventual use in stem cell therapy (Narasipura et al. 2008; 
Wojciechowski et al. 2008). An appropriate dosage of nanoscale liposomes mixed 
with the enriched sample would help eliminate the tumor burden while sparing the 
patient with the complications of graft-versus-host disease that is a concern with bone 
marrow transplant therapy. 
Since TRAIL belongs to the TNF superfamily, TRAIL may cause 
inflammation similar to that of TNF-" treatment. Thus interaction of liposomes with 
endothelial cells may lead to undesired results. In addition, endothelial cells express 
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sLea/x that binds to E-selectin thus a potential for interaction of liposome with the 
endothelium is possible. While no specific measurements on the effects of the 
nanoscale liposomes on the endothelial cells were made in this study, in a recent study 
(Li et al. 2003), human umbilical vein endothelial cells from the umbilical vein and 
human dermal microvascular endothelial cells when treated with TRAIL showed 
negligible effect on the viability of the endothelial cells, however, an increased 
expression of E-selectin and ICAM-1 was seen suggesting that TRAIL may be 
activating endothelial cells. In contrast, Secchiero and coworkers demonstrated that 
TRAIL promotes the survival and proliferation of primary human vascular endothelial 
cells by activating the Akt and the ERK pathways. They found no difference in the 
surface expression of E-selectin and ICAM-1 (Secchiero et al. 2003). The difference 
in endothelial activation via TRAIL treatment may be due to the difference in the 
source of the endothelial cells. Moreover, Li et al. focused on the gene expression 
while Secchiero et al. looked at surface expression of receptors. While the effect of 
TRAIL on endothelial cells may be uncertain and may depend on the type of 
endothelial, interactions with the endothelium are possible when injected systemically.  
Liposomes discussed in this work are efficient in killing cancer cells both in 
buffer and when spiked in whole blood (figure 4.4 and 4.6). It should be noted that the 
liposomes are particularly effective against cancer cells when spiked in whole blood. 
While in interaction of the immune cells with the cancer cells is possible, but more 
likely explanation is the increased collision of liposomes with a greater density of cells 
in whole blood spiked with cancer cells. One may argue that there may be a diluting 
effect of the liposomes considering that there are at least an order of magnittude higher 
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blood cells. RBC which are the majority fraction of blood cells do not interact with E-
selectin and hence are incapable of binding with the liposomes. The remainder of the 
cells may interact with E-selectin but are killed by TRAIL (Figure 4.5). These cells 
then owing to their larger size and greater numbers have a greater probability of 
collision with cancer cells. There is a possibility of the by-stander effect as has been 
discribed by Bremer and co-workers (Bremer et al. 2004; Bremer et al. 2005). 
When liposomes attach to the peripheral blood MNCs, there is a possibility of 
aggregates of MNCs being formed. These aggregates may be comparable in size to 
viable cancer cells. The gating strategy followed is based on forward scatter and side 
scatter parameters of the flow cytometer hence there is a possibility of detecting false 
positives thus, under representing the kill rate.  
Over all the work described in this chapter presents compelling evidence to 
further pursue liposomal delivery of TRAIL. This work has demonstrated that the 
liposomes can target cancer cells under shear without any effect to peripheral blood 
mononuclear cells. Conjugating different molecules to the liposome, different cancers 
can be targeted, including the primary tumor can expand the scope of this work. 
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4.5 Conclusions 
Inspired by the TRAIL mediated tumoricidal activity of NK cells, we have 
developed nanoscale lipid particles that would target circulating cancer cells and 
induce apoptosis to them. We have demonstrated that these lipid nanoscale particles 
lipids do not have any significant effect on peripheral blood MNC. In addition, we 
have demonstrated that the naked nanoscale liposomes or with just E-selectin do not 
kill cancer cells. When the liposomes were conjugated with just TRAIL, a negligible 
amount of death was observed under shearing conditions. When conjugated together 
with E-selectin and TRAIL, a kill rate of over 50% was observed in just two hours. 
These results suggest that the combination of E-selectin and TRAIL, creating a two-
receptor nanoscale lipid particle, is required for delivery of the receptor-mediated 
apoptosis signal. Finally, we demonstrated that the nanoscale liposomes demonstrate a 
greater efficiency in  killing cancer cells when spiked into blood, possibly due to 
increased collisions in blood. Taken together, these results suggest exciting 
possibilities in cancer treatment for targeting circulating tumor cells. 
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Table 4.1. Composition by weight percent of liposomes 
DOGS NTA-Ni Egg PC Egg SM Chol/Bdp-Chol* 
0% NTA 60 30 10 
1% NTA 59 30 10 
5% NTA 55 30 10 
10% NTA 50 30 10* 
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Figure 4.2 : Characterizations of the attachment of TRAIL to nanoscale lipo-
somes. Supernatant from the ultracentrifugation step was collected and added to 
Colo205 in culture. (A) Percent viable Colo205 cells after a 24 hour treatment with 
supernatant under static conditions. Results are average ± SEM, n=3. (B-E) Rep-
resentative flow cytometry plots of viability of Colo205 after treatment with super-
natant obtained from (B) 0% NTA, (C) 1% NTA, (D) 5% NTA and (E) 10% NTA. 
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without liposomes
0% NTA
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F
Figure 4.2 :(F) Micrographs of cells in culture after 24 h of treatment 
with supernatant from 0% NTA and 10%NTA. When compared to the 
control conditions without liposomes, a greater number of cells 
fragments are seen when Colo205 are treated with supernatant from  
0% NTA and almost none when treating with supernatant from 10% 
NTA sugesting almost complete binding of TRAIL onto the 10% NTA 
liposomes.  Scalebar is 50 μm.
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Figure 4.3 : Efficiency of TRAIL bound nanoscale liposomes in killing cancer 
cells over a 24 h period under static conditions. (A) Percent viable Colo205. 
Results are average ± SEM, n=3. (B-E) Representative flow cytometry plots 
showing viability of Colo205 when treated with (B) 0% NTA, (C) 1% NTA, (D) 
5% NTA and (E) 10% NTA. 
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Figure 4.3 : (F) Micrographs of Colo205 cells in culture after 24 h treatment 
with TRAIL bound nanoscale liposomes. Scalebar is 50 μm.
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Figure 4.4 : Shearing nanoscale liposomes with cancer cells suspended in buffer in 
a rotating cone-and-plate viscometer at a shear rate of 75 s�� for 2 h. (A) Results from 
sheared nanoscale liposomes. Results are average ± SEM, n=3.  (B-F) Representa-
tive flow cytometry plots showing the viability of (B) cells that were not subjected to 
any shearing condition, (C) cells that were sheared with liposomes that were not 
conjugated to any protein, (D) cells that were sheared with liposomes that were 
conjugated to TRAIL alone, (E) cells that were sheared with liposomes conjugated 
with E-selectin alone and (F) cells that were sheared with liposomes conjugated with 
both TRAIL and E-selectin.
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Figure 4.5 : Binding of liposomes to Colo205 cells at a shear rate of 75 s��. (A) 
Colo205 cells were sheared with and without fluorescent liposomes. Results 
plotted are average ± SEM, n=3. (B) Representative histograms showing brighter 
fluorescence from cells that were sheared with fluorescent liposomes (green) 
conjugated with TRAIL + E-selectin when compared to cells that were sheared 
with non-fluorescent liposomes lacking TRAIL + E-selectin. (C-D) Effects of 
nanoscale liposomes on viability of human MNCs isolated from peripheral blood of 
healthy adults (C) under static conditions after 24 hours of culture and (D) 24 h 
after shear exposure. To isolate the effects of shear on MNCs, viability is shown 
with unsheared cell that were not subjected to shearing forces. 
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Chapter 5 Conclusions and future directions 
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Collectively, in this work, I have demonstrated two novel biomimetic methods 
to kill cancer cells. Both methods, in one form or the other, exploit the naturally 
occurring phenomenon of cancer cell interaction with the endothelium via the selectin 
family of proteins. Using E-selectin and TRAIL, methods have been designed that 
would promote capture of - or attachment to - fast moving cells. Once, attached to 
either the functionalized surface or the liposome, the cell will come in contact with 
TRAIL and via death receptors will undergo apoptosis.. These methods are as yet 
proof-of-concept and several improvements are necessary before any of these methods 
could become clinical applications for cancer treatment. Conclusions derived from this 
work are summarized in this Chapter along with some future directions. 
5.1 Biomimetic Cell Neutralization Device 
In Chapter 1, I have discussed the process of hematogenous metastasis and the 
role selectins in metastasis. Briefly, one of the methods by which cancer cells in 
circulation interact with the vessel endothelium is similar to how neutrophils interact 
with the endothelium under an inflammatory response (Barthel et al. 2007; Gout et al. 
2008; Orr et al. 2000). While under flow, cancer cells are pushed towards the 
endothelium by the more deformable red blood cells that push the less deformable 
cells like leukocytes and cancer cells towards the vessel wall (Gentile et al. 2008). 
This process is called margination. Once the cells interact with the endothelium via 
selectins, they progressively slow down and eventually they come to firm arrest (i.e. 
stop rolling) (Ley et al. 2007). The cancer cells may then transmigrate and potentially 
form a secondary tumor.  Exploiting the phenomenon of cancer cell interaction with 
selectins on the endothelium, in Chapters 2 and 3, I demonstrated proof-of-concept for 
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a device that would capture fast moving cells under flow using the principles of 
margination and selectin-mediated interactions of cancer cells and ultimately kill them. 
Using the leukemic cell line HL60 (Chapter 2) and a colon cancer cell line 
Colo205 (Chapter 3) I demonstrated that it is possible to capture flowing cells and that 
cells interact with selectins and in particular E-selectin. Appendix II lists some other 
cells lines that interact with selectins and could be sensitive to TRAIL by the 
mechanism used here. 
Using the AML cell line HL60, I demonstrated that in a short duration of 1 h 
rolling over a surface functionalized with TRAIL and E-selectin, 30% of the captured 
HL60 cells are killed. Furthermore, it would take at least 4 h to achieve a similar kill 
rate without flow over a similarly functionalized surface. I believe this is due to a 
larger area of the cell being exposed to TRAIL when rolling than under static 
conditions. Alternatively, while rolling, the cancer cell may be exposed to multiple 
TRAIL molecules and consequently the cell might be receiving multiple signals that 
result in a faster death to rolling cancer cells compared to static conditions. 
Zamai and co-workers have shown that TRAIL negatively effects 
erythropoiesis (Zamai et al. 2000). Since most blood cells are derived form either 
BFU-E or CFU-GM colonies, a long term culture in semisolid media was used to 
evaluate the effect of TRAIL on the ability to form blood cells. TRAIL treatment did 
not alter the number of CFU-GM and BFU-E colonies in long-term (14 days) culture 
assay. BFU-E and CFU-GM colonies form majority of blood cells. In addition, 
TRAIL does not significantly affect viability of both adult CD34+ and adult CD34- 
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bone marrow cells in short term cultures of 48 h. Flowing peripheral blood MNCs 
through the device for a period of 1 h did not kill the perfused cells. These results 
suggest that the device does capture blood cells, however the device with immobilized 
TRAIL does not exert any cytotoxic effect on non-cancerous cells.  
In addition to serving as adhesion molecules, selectins are also involved in 
signaling and activation of neutrophils by shedding L-selectin and consequently 
activating integrins (Lee et al. 2007). L-selectin interacts with E-selectin (Chapter 1), 
hence in order to evaluate the effect of L-selectin - E-selectin interaction on PMNs, 
PMNs isolated from peripheral blood were perfused over the functionalized surface 
for 2 h. Results show a decrease in the surface expression of L-selectin. This 
phenomenon is described in more detail by Lee et al. (Lee et al. 2007). While the loss 
of L-selectin is considered an initial step in the activation cascade, the loss of L-
selectin also downregulates the cells’ adhesiveness to endothelial cells (Zouki et al. 
1997). The expression of active !2 integrins was not significantly different from 
controls. These results suggest that the device does cause L-selectin shedding, 
however the propensity to arrest on ICAM-1 should not be increased.  Loss of L-
selectin would compromise the immunosurveillance function of leukocytes and this 
aspect needs to be studied further.  
I have also demonstrated that the proposed device is able to capture and kill 
colon cancer cells. Using the colon cancer cell line Colo205, I demonstrated that over 
a period of 1 h, 15% of the captured cancer cells were killed. When Colo205 cells 
were perfused over the combined TRAIL - E-selectin surface for 2 h, the kill rate 
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increased from about 15% to 45%; a three fold increase in kill as predicted in Chapter 
2.  
Surgery is one of the most commonly used methods of tumor removal and 
cancer treatment. However, surgery been shown to disseminate new tumor cells into 
the circulation (Yaw et al. 1975). Implanting the device prior to surgery could reduce 
the risk in the spread of cancer caused by surgery. 
For patients with leukemia, one of the available treatments methods includes 
stem cell transplantation (Copelan 2006). Allogeneic bone marrow transplants run the 
risk of host rejection while autologous bone marrow transplants run the risk of 
reintroducing cancer cells (Bosi and Bartolozzi 2010; Wingard et al. 2010). The use of 
the device ex vivo to process cell samples prior to bone marrow transplant would 
prevent the reintroduction of cancer cells. 
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5.2 Combined Treatment Scenario 
Cancer cells, in time, develop resistance to chemotherapy (Di Pietro et al. 
2001; Gilbert and Hemann 2010; Van Geelen et al. 2004). However, such treatments 
in turn sensitize cancer cells to TRAIL-mediated apoptosis by upregulating pro-
apoptosis proteins, downregulating pro-survival proteins, upregulating death receptors 
or other methods (Di Pietro et al. 2001; Jeon et al. 2003; Keane et al. 1999; Koschny 
et al. 2007; Lu et al. 2008; Mitsiades et al. 2001; Nagy et al. 2006; Wen et al. 2000). 
Studies have shown synergistic effects of pre-treatment with pharmaceuticals 
(Koschny et al. 2007; Nagy et al. 2006). Aspirin has been shown to sensitize cancer 
cells to TRAIL (Kim et al. 2005; Lu et al. 2008; Yoo and Lee 2007).  
When colon cancer cells were pretreated with 1 mM aspirin for 18 h and then 
perfused over the combined TRAIL and E-selectin surface for 1 h, 45% of the 
captured cells were killed compared to cells that were perfused on the E-selectin only 
surface. It should be noted that the kill attributed to aspirin treatment alone was about 
3 – 5% and that of perfusing untreated Colo205 cells over the combined surface of 
TRAIL – E-selectin was about 15% Colo205 when compared to control with only E-
selectin. Colo205 cells were perfused over the surface, over 90% kill was observed in 
2 h, indicating a synergistic effect of TRAIL and aspirin. In both cases a synergistic 
(i.e., super-additive) effect is seen. These results are very promising for further 
exploring the effects of aspirin and the development of the microtube device. 
In investigating the aspirin sensitization to TRAIL-mediated apoptosis; no 
change in death receptor expression in Colo205 cells was seen. Researchers have 
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previously shown that aspirin downregulates survivin or Bcl-2 gene (Kim et al. 2005; 
Yoo and Lee 2007). However, in my work, I found that multiple pro-survival proteins 
were downregulated simultaneously. BCL-2 downregulation was to the greatest extent, 
while survivin was the least. 
Bortezomib, also called Velcade™, has been shown to be effective in 
treatment of leukemia while also sensitizing leukemic and colon cancer cells to 
TRAIL mediated apoptosis (Koschny et al. 2007; Mackay et al. 2005; Nagy et al. 
2006). Appendix I summarizes results from combined treatment study with HL60 cells 
pretreated with bortezomib. As with aspirin treatment, results suggest a super-additive 
effect with pretreatment with bortezomib. It should be noted that the EC50 was 
determined to be around 8 ng/mL for HL60 cells while the treatment was given at a 
dosage much lower than EC50. Taken together these results suggest the possibility of 
reducing chemotherapeutic dosage while maintaining sufficiently high kill rates.  
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5.3 Nanoscale lipids decorated with TRAIL and E-selectin 
While Chapters 2 and 3 focus on capturing cells in circulation using a 
functionalized microtube device, Chapter 4 discusses the use of nanoscale liposomes. 
As described in Chapters 2 and 3, when cells make contact with the functionalized 
surface and interact with TRAIL. This interaction causes the cells to undergo 
apoptosis. This method is an attractive option when the likely site where the cancer 
cells prefer to metastasize is easily accessible. However in cases where multiple 
preferred sites exist or the preferred site may not be easily accessible (like bone 
metastasis) a different approach to targeting metastatic cancer cells is demonstrated in 
Chapter 4 using nanoscale liposomes decorated with TRAIL and E-selectin. 
In the final part of my dissertation, I developed nanoscale lipids bearing 
TRAIL and E-selectin. These liposomes bind with high efficiency to Colo205 cells 
under shear. Over 95% of Colo205 were bound to liposomes when subjected to a 
uniform shear at a shear rate of 75 s-1 for 2 h. When Colo205 suspended in buffer and 
mixed with either TRAIL + E-selectin-bearing liposomes or control (naked liposomes 
(no protein), E-selectin-bearing liposomes and cells that were not subjected to 
shearing conditions) a 50% kill rate was observed over the control conditions. 
Liposomes with only TRAIL, however, killed a small percentage (3-5%) over the 
control conditions. When Colo205 cells were spiked in healthy adult peripheral blood 
and sheared at 188 s-1 for 2 h, over 90% of the cells were found dead. No significant 
effect of the liposomes on peripheral blood MNC was observed when subjected to 
shear for 2 h or cultured under static conditions for 24 h with the TRAIL + E-selectin-
bearing liposomes.   
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5.4 Future Directions 
The proposed device (Chapters 2 and 3) and its applications are still at the 
proof-of-concept stage. Further improvements and testing is necessary for the 
applications to be commercialized and used in a clinical setting. Though the device is 
particularly efficient in capturing cells and killing cancer cells, the device geometry is 
not optimal. The geometry, though simple and easy to use, is limited by (1) optimum 
diameter to facilitate margination and (2) available surface area. 
Previously researchers have demonstrated that the optimum diameter for 
effective margination in vivo is about 30 µm (Ley and Gaehtgens 1991; Nobis et al. 
1985). While these studies were performed for leukocytes, optimizing the diameter for 
cancer cells will be necessary. Leukocytes are typically around 8 µm in size, cancer 
cells tend to be much larger; usually between 10 – 25 µm (personal observation). 
Optimizing the diameter would promote margination and hence interaction with the 
surface. However, the desire for effective cell margination must be balanced with 
minimizing the risk of flow device occlusion by large cellular aggregates. 
The microtube flow device described in this thesis is limited in terms of the 
available surface area. Once the available area is saturated, recruiting additional cells 
is not possible. The King laboratory has been working on modifying the nanoscale 
topography of these microtubes (Han et al. 2010; Hughes and King 2010). These 
nanoscale changes increase the available surface area and help capture the cells earlier 
by overcoming the lubrication layer without changing the overall fluid dynamics. The 
increased surface area also promotes enhanced capture of cells.  
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One obvious next step in the development of the device is to consider 
interactions of cancer cells with blood. Spiking cancer cells in blood will help to 
elucidate the limits of device performance and shed light on the interactions within the 
complex environment of blood. While in blood cancer cells are know to interact with 
platelets and leukocytes shielding them from the functionalized surfaces (Bastida and 
Ordinas 1988; Geng et al. 2010; Slattery et al. 2005). A modified version of this 
device has been shown to capture cancer cells with a very high efficiency (King et al. 
2009). However, the numbers of cells recovered are very few in number and 
inconsistent between runs. In addition, blood has soluble selectin ligands (e.g. PSGL-
1) that inhibit the adhesion of cancer cells to the functionalized surface (Narasipura 
and King).  Based on personal observations, at least 50,000 cancer cells are required 
for analysis via flow cytometry. When spiking in blood recovery is not high enough 
for analysis. More sensitive techniques like Q-PCR capable of detecting very few cells 
may help with analysis. Researchers have demonstrated that using Q-PCR as few as 
10 colorectal cells spiked in 14 mL of blood (Tsavellas et al. 2002). 
Furthermore, the device currently relies on passive adsorption of proteins. 
Passively adsorbed selectin proteins have been shown to be functional for up to 24 h 
(Wojciechowski et al. 2008). Over the duration of the experiments in this thesis no 
noticeable leaching of the proteins was observed, however, for extended duration (>24 
h) a more permanent form of attachment will be necessary. Hong et al., working in 
conjunction with the King Laboratory have demonstrated covalent immobilization P-
selectin to glass surface (Hong et al. 2007). One challenge with adapting those 
chemistries to the device lies in the fact that selectins have an active site on the N-
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terminus while that of TRAIL is the C-terminus. Alternate attachment methods need to 
be explored. TRAIL based peptides are also shown to be effective and may be used 
(Aina et al. 2007; Okochi et al. 2006). Peptides, being smaller molecules than intact 
proteins, are more stable and improve shelf life of the device.  
The ultimate test for device effectiveness would be in human clinical trials. 
However, before being used in human, studies with animal models are required. As an 
initial study, cells perfused through the device could be collected and then injected 
into animals to evaluate tumor forming potential of the injected cells. Alternatively, 
the microtube device may be implanted into the animal implanted with a metastatic 
tumor. The King research group has previously demonstrated use of such implantable 
device to capture CD34+ cells from rat blood (Wojciechowski et al. 2008). 
The alternative approach of targeting metastasis using freely diffusing 
liposomes decorated with TRAIL and E-selectin is built on the assumption that cancer 
cells interact with E-selectin. However, several cancers types do not rely on selectins 
for metastasis or may express surface markers specific to a particular type of cancer. 
Such cancer cells may be targeted by changing the surface decoration of the cancer 
cells (e.g. cells of epithelial origin express EpCAM, prostate cancer cells express 
PSMA, etc). 
Successful use of liposomes requires that the liposomes remain in circulation 
for an extended period of time (t! > 15 h with PEG compared to t! = 30 – 60 min for 
TRAIL) (Allen et al. 2002; Xiang et al. 2004). However, extremely long circulation 
times (14 – 21 days as with TRAIL-R antibodies) may lead to toxicity (Mori et al. 
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2003; Takeda et al. 2008). This requires creating so-called “stealth” liposomes by 
adding PEG to the liposomal surface (Immordino et al. 2006). The nanoscale 
liposomes as described in this thesis do not contain PEG and therefore may be more 
susceptible to be removed by human body.  
The current attachment method relies on the interaction of His tag and and Ni-
NTA. If the metal ion was chelated, the protein would then detach. Huang and King 
have shown similar nanoscale liposomes that used covalent attachment of P-selectin 
(Huang and King 2009). This attachment chemistry depends on modifying primary 
amines present on the proteins. However modifying primary amines may not provide 
adequate control over the orientation of the proteins. Chemistries involving the N-
terminus and C-terminus may prove to be beneficial in this case. Constructing 
liposomes allows the use of different lipids and hence the attachment proteins with 
different chemistries can be more facile than implementation on a flow device surface.  
As with the microtube device, the ultimate test of any therapy is proven with 
human clinical trial. I have demonstrated the efficacy of liposomes in spiked blood, 
however the performance in a live animal would set the stage for further 
pharmacological (PK/PD) studies, with the hope of eventually seeing this application 
as a therapy for cancer. 
The number of circulating cancer cells (CTC) has been related to the progress 
of the diseases. Generally, to treat metastatic disease, systemic chemotherapy or 
radiation is prescribed. In this study, I have shown ways to target cells in circulation. 
By eliminating these CTCs one would prevent formation of secondary tumors in 
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general, thus allowing the oncologist to concentrate on the primary tumor. This study 
encompassed the early stages of product development of a selectin and TRAIL-based 
methods to target and neutralize CTCs. Further optimization of the methods as well as 
extensive investigations into binding chemistry, in vivo studies and stability studies 
are necessary next steps to creating an acceptable commercial product. 
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I.0 Abstract 
Circulating tumor cell (CTC) numbers in blood have been correlated to poor 
prognosis for the patient as these CTCs may eventually form secondary tumors – the 
reason for most cancer-related deaths.  One way for tumors to spread is through 
metastasis via the circulatory system. CTCs are able to exploit the natural leukocyte 
recruitment process that is initially mediated by rolling on transient selectin bonds. 
Once cells are captured by E-selectin, they interact with TRAIL (Tumor Necrosis 
Factor-Related Apoptosis-Inducing Ligand or Apo2L) on the surface that eventually 
triggers a receptor-mediated biochemical signal to neutralize the cancer cell. In 
Chapter 2, I have demonstrated that using a combined E-selectin and TRAIL 
functionalized surface, 30% of the captured cells were killed. The preliminary study in 
this Appendix was intended to explore the possibility of using the device as an 
adjuvant therapy in which the patient is under chemotherapy. I demonstrated that with 
very small doses of the chemotherapeutic agent bortezomib, a synergistic effect of 
killing 48% cells in 1 h is possible. Thus, the in vivo process of selectin-mediated 
CTC recruitment to the vessel wall in distant tissues can be used to target CTC to 
reduce-blood borne metastasis load. 
 
Keywords: cell capture, apoptosis, cancer, cell rolling 
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I.1 Introduction 
Metastais is the major reason for cancer-related deaths. The metastatic cascade 
involves multiple steps that eventually lead to disseminating cancer cells into the 
circulation. There are three general steps in metastasis through the circulatory system 
(Zieglschmid et al. 2005). First, cancer cells become less adherent to each other thus 
allowing them to detach from the primary tumor. In addition, the cells secrete factors 
that stimulate angiogenesis to promote entry into the bloodstream. Once the cells 
intravasate into the bloodstream they are referred to as circulating cancer cells (CTC). 
Lastly, they may adhere to the vascular endothelium via primary binding with selectin 
proteins and secondary binding with integrin or MUC-1 receptors. Once adhered, CTC 
have the opportunity to extravasate into surrounding tissues.  
The family of selectin proteins mediates the initial recruitment step of CTCs to 
the vessel wall during metastasis through the bloodstream, similar to the tethering and 
rolling of leukocytes in the inflammatory cascade (Barthel et al. 2007). Selectins are 
single-pass transmembrane proteins with an extracellular amino terminal C-type 
domain followed by an epidermal growth factor-like domain, two to nine short repeat 
domains, a membrane spanning domain, and finally a cytoplasmic tail (Kansas 1996). 
There are three types of selectin: P-, E-, and L-selectin. P-selectin is stored in granules 
in platelets and endothelial cells. E-selectin is synthesized by endothelial cells de novo 
in response to inflammatory stimulation by TNF- , while L-selectin is constitutively 
expressed on leukocytes. 
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TNF-Related Apoptosis-Inducing Ligand (TRAIL) or Apo2L is a type II 
transmembrane protein that has recently gained attention due to its tumoricidal activity 
(Ashkenazi et al. 1999; Walczak et al. 1999). TRAIL is known to bind to five 
receptors; two decoy receptors (DcR1 or TRAIL R3 and DcR2 or TRAIL R4) and two 
death receptors (DR4 or TRAIL R1 and DR5 or TRAIL R2). The fifth receptor is 
OPG, which has a role in bone remodeling (Newsom-Davis et al. 2009). The decoy 
receptors that have a short, non-functional cytoplasmic tail incapable of recruiting the 
adaptor proteins to initiate the apoptosis pathway (Plasilova et al. 2002), while the 
death receptors upon binding with TRAIL trimerize. Trimerization of the receptor 
allows the recruitment of the adaptor proteins necessary to initiate the caspase 
dependent apoptosis pathway. TRAIL was first identified based on its homology to 
Fas ligand (FasL). However, unlike FasL, TRAIL exerts its tumoricidal activity on 
transformed cells but not on healthy cells (Ashkenazi et al. 1999). 
The use of proteasome inhibitors to target cancer cells has gained sufficient 
interest (Adams 2004). Bortezomib (also called Velcade or PS-314) is a dipeptidyl 
boronic acid that specifically inhibits proteasome 26S and has shown promise in 
treatment of patients with leukemia and multiple myeloma and is under clinical trials 
for use in solid tumors (Curran and McKeage 2009; Heaney et al. 2010; Mackay et al. 
2005). When cancer cells are pre-treated with chemotherapeutic drugs such as 
bortezomib, a synergistic effect with TRAIL has been seen (Koschny et al. 2007).  
Few methods exist to reduce blood borne metastatic load. Existing methods to 
reduce this load rely on filtration of blood through extracorporeal devices to weed out 
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CTCs. Such methods, though effective, are associated with patient discomfort and 
require frequent hospital visits (Edelman et al. 1996; Fruhauf et al. 2001; Perseghin et 
al. 1997). Since these methods do not remove cells in a continuous manner but rather 
in batches, a buildup of tumor forming cells is possible between treatments. The 
method described here aims at developing an implantable device that could kill cancer 
cells on a continuous basis (Chapters 2 and 3). 
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I.2 Materials and Methods 
I.2.1 Reagents and antibodies 
Human serum albumin (HSA), bovine serum albumin (BSA), HEPES, EDTA 
and CaCO3 were all obtained from Sigma-Aldrich (St Louis, MO). RPMI 1640 cell 
culture media, fetal bovine serum (FBS), 1X Trypsin, Penicillin-Streptomycin 
(PenStrep), Hank’s balanced salt solution (HBSS) and phosphate buffered saline 
(PBS) were all obtained from Invitrogen (Grand Island, NY). His-tagged recombinant 
human TRAIL,, recombinant human E-selectin-IgG chimera and TACS Annexin-V 
FITC Apoptosis Detection Kit were purchased from R&D Systems (Minneapolis, 
MN). Protein-G and anti-His tag antibody were purchased from EMD Biosciences 
(San Diego, CA).  
I.2.2 Cell lines and cell culture 
Acute Myeloid Leukemic (AML) cell line HL60 (ATCC number CCL-240), 
was obtained from ATCC (Manassas, VA). Cells were cultured in RPMI 1640 
supplemented with 2mM L-Glutamine, 25mM HEPES, 10% v/v FBS and 100 U/mL 
PenStrep (complete media) under humidified conditions at 37˚C and 5% CO2. HL60s 
were cultured in suspension such that the cell count did not exceed 106 cells/mL  
I.2.3 Cell preparation for experiments 
HL60 cells were washed twice with 1X DPBS at 200xg in Allegra X-22 
refrigerated centrifuge at 4˚C and resuspended in flow buffer at a concentration of 106 
cells/mL. The flow buffer consisted of HBSS without Ca2+ and Mg2+ supplemented 
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with 0.5% w/v HSA, 10mM HEPES and 2mM CaCO3. For rolling experiments, at 
least 90% viability of cells was confirmed by trypan blue exclusion dye. 
HL60s were split and cultured for 24 h to ensure cells were in the linear phase of their 
growth. AML cell line was treated with varying dosages of bortezomib (obtained from 
Dr. Jane L. Liesveld, University of Rochester) for 16 h and the cells were either 
analyzed for viability by the annexin-V assay or used for rolling experiments. Dosages 
used for clinical trails in patients with leukemia were 1.3 mg/m2/dose (Horton et al. 
2007). 
I.2.4 Preparation of immobilized protein surfaces 
Recombinant human E-selectin-IgG (rhE-selectin) was dissolved in DPBS to a 
final concentration of 100 !g/mL. In addition, stock solutions of TRAIL (rhTRAIL), 
protein-G and anti-His tag antibody in PBS were prepared at 20 !g/mL, 100 !g/mL 
and 200 !g/mL respectively. Aliquots of the stock solutions were stored at –20 ºC and 
used as needed within 60 days. The surface was first incubated with 10 !g/mL 
protein-G solution for 1.5 h, followed by a 2 h incubation with rhE-selectin  (0.1 - 5 
!g/mL) or a combination of rhE-selectin and anti-His tag antibody  (5 !g/mL and 10 
!g/mL respectively), and then the surface was incubated with 2 - 20 !g/mL rhTRAIL 
solution. Each incubation step was followed with three washes with DPBS. All 
incubations were conducted at room temperature. 
I.2.5 Rolling experiments  
Micro-Renathane tubing 300!m internal diameter tubing obtained from 
Braintree Scientific (Braintree, MA), was cut into 50 cm segments and secured to the 
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stage of an inverted motorized microscope (Olympus America Inc., Melville, NY). 
The microscope was equipped with a CCD camera (Model No: KP-M1AN, Hitachi, 
Japan) connected to a DVD recorder (Model No: DVO-1000MD, Sony Electronics, 
Park Ridge, NJ) to facilitate image capture for offline analysis. A syringe pump (KDS 
230, IITC Life Science, Woodland Hills, CA) was used to control flow rate of the cell 
suspension. Cells were loaded on the surface at a shear stress of 0.5-1 dyne/cm2 for 3 
min following which the flow experiment was performed. Flow experiments on 
functionalized capillary flow chamber surfaces were performed at 2.5 dynes/cm2, for a 
period of 1 h. At the end of 1 h, cells were categorized into two fractions, “cells on 
surface” – cells that were rolling on or remained on the surface at the end of the 
experimentation period and “cells in flow” – cells that were collected in the syringe.  
The cells on the surface were harvested using 5 mM EDTA and air embolism 
at 10 dyne/cm2. These cells were then cultured in complete media for 16 h and 
analyzed by Annexin-V assay. rhE-selectin and His-tag antibody (without rhTRAIL) 
functionalized surfaces were used as negative controls. 
I.2.6 Data analysis 
“Rolling” cells were defined as those observed to translate in the direction of 
flow with an average velocity less than 50% of the calculated hydrodynamic free 
stream velocity. Rolling flux was determined by counting the number of cells crossing 
a line drawn in the field of view perpendicular to the flow direction, over a period of 1 
min. 
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 All cell experiments were analyzed by Annexin-V apoptosis assay on a BD 
FACSCaliber or Guava EasyCyte Mini flow cytometer. Manufacturer’s instructions 
were followed to prepare samples for analysis. Based on the dye taken up by cells, 
they were classified into four categories: viable cells (negative for Annexin-V and PI), 
early apoptotic cells (positive for Annexin-V only), late apoptotic cells (positive for 
Annexin-V and PI) and necrotic cells (positive for PI only). 
Where appropriate, the student’s t-test was employed at significance level of ! 
= 0.05. Non-linear regression was employed for determining EC50 using GraphPad 
Prism. All statistical analyses were performed using GraphPad Prism 5.0c for Mac OS 
X GraphPad Software (San Diego, CA USA, www.graphpad.com.) 
  
 187 
I.3 Results 
I.3.1 Dose response of HL60  
HL60s in culture were treated with 0 – 25 ng/mL of Bortezomib for 16 h and later 
analyzed for viability by the annexin-V assay (Figure I.1). With increasing dosages of 
Bortezomib, the viability decreased. There was no significant difference in the 
decrease in viability between treatments with 20 ng/mL and 25 ng/mL The 
concentration required to kill 50% of HL60 (EC50) with 16 h bortezomib treatment 
was determined to be around 8 ng/mL using nonlinear regression. 
I.3.2 Flow experiments with Bortezomib pre-treatment 
HL60 pretreated with Bortezomib for 16 h, were washed and resuspended in flow 
buffer at 106 cells/mL and perfused through the microcapillary flow device at a wall 
shear stress of 2.5 dyne/cm2 for 1 h. After the duration of flow, cells were collected 
and cultured in complete media for 16-20 h at culture conditions. These cells were 
then analyzed for viability. Figure I.2A summarizes the results obtained. Briefly, when 
cells were perfused over the control surface lacking TRAIL, ~ 5% cells were found to 
be dead, while those treated with 3 ng/mL of Bortezomib were ~ 9% dead. HL60s not 
treated with bortezomib when perfused over the combined surface of TRAIL + E-
selectin killed 30% cells while HL60 cells pre-treated with bortezomib for 16 h when 
perfused over the combined surface of TRAIL + E-selectin, the device killed about 
48% of the captured cells. These results show superadditive effects of treating HL60 
cells with sublethal dosages of Bortezomib.  
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I.4 Discussion 
In Chapter 2, I demonstrated that with the microtube device it is possible to kill 
about 30% of the captured cells when processing a suspension of untreated HL60 cells 
without any significant effect to other cells in blood including CD34+ hematopoietic 
stem cells. In addition, previously it has been demonstrated that rolling delivery is 
more potent than static exposure (Chapter 2). Here I extended the previous work by 
showing the feasibility of using this device in combined treatment scenarios.  It is 
important to note that HL60s are being treated with Bortezomib at concentrations 
much lower than the determined EC50.  
In a separate experiment, we tested the toxicity of Bortezomib to AML cells in 
culture and found that 3 ng/mL Bortezomib treatment for 16 hours is sufficient to kill 
around 5-8% of the cells.  We see an additive effect in the kill rate of HL60 cells under 
flow over a TRAIL – E-selectin surface, with ~8% cell death being attributed to 
Bortezomib and the remaining 40% due to interaction of Bortezomib treated cells with 
the combined TRAIL and E-selectin surfaces. Previously Nagy et al. and Pitts et al. 
have demonstrated synergistic effects of bortezomib + TRAIL treatment in static 
conditions ( Nagy et al. 2006; Pitts et al. 2009). In this report, this synergistic effect is 
utilized to deliver TRAIL to rolling cancer cells. 
It is expected that the microtube device could be customized to specific cancer 
types by varying the amount and type of adhesion molecule used. The difference of 
48% was obtained when HL60 cells were pretreated with dosages below EC50 
(treatment dose = 3 ng/mL, EC50 = 8 ng/mL) in static culture. Taken together, results 
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indicate that when used in combination with the device, the amount of 
chemotherapeutic agent given may be reduced. 
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I.5 Conclusions 
Though these results are preliminary, the study demonstrates the possibility of 
decreasing the dosages of chemotherapeutic agent use in combination with the 
microtube device functionalized with TRAIL + E-selectin. Looked at from a different 
perspective, any cells surviving chemotherapy that contact a selectin + TRAIL surface 
such as that tested, would most likely be neutralized by the microtube device. 
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Figure I.1 : Dose response of HL60 to bortezomib treat-
ment for 16 h in culture. Results are average ± SEM, n=3 
for each point. 
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A
Figure I.2 : Pre-treating cells with very small doses of bortezomib enhances 
the killing of HL60 cell when perfused through the device. (A) Percent dead 
cells after 1 hr of rolling on the functionalized surface. Results are average 
± SEM, n=3. (B-E) Representative flow cytometry plots showing increased 
kill when pretreated cells were perfused through the TRAIL + E-selectin 
functionalized surface.
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II.1 Cell lines responsive to adhesion molecules 
 
Cancer Type Line Source Ref Notes 
Colon Carcinoma Colo 320 Human doi:10.1016/j.yexcr.2
006.09.008 
PS activates integrin 
mediated cell 
adhesion 
Colon Carcinoma HT-29 Human doi:10.1023/B:CLIN.
0000037708.09420.9
a 
Adhesion to 
endothelial via ES 
Colon Carcinoma KM12-C 
KM12-SP 
KM12-SM 
KM12-L4 
Human J. Biol. Chem. Saitoh 
et al. 267 (8): 5700 
Adhesion via ES. 
Experiments with 
mouse model 
Colon Carcinoma LS-180 Human PMID: 11485302  
Lewis Lung 
Carcinoma 
H-59 
M-27 
 Int. J. Cancer:71 612 
(1997) 
Adhesion via ES 
Colorectal 
Carcinoma 
HM-7 
LS174T 
CX-1 
 Int. J. Cancer:71 612 
(1997) 
Adhesion via ES 
Adenoid Cystic 
Carcinoma of 
Salivary Gland 
Acc-M Human J. Immunol. 2002, 
168, 1690 
PS adhesion 
Breast Cancer KS Human Blood 89 (9): 3385. 
(1997) 
Selectin ligand 
expressing 
Small Cell Lung 
Carcinoma 
SW2 Human Blood 89 (9): 3385. 
(1997) 
Selectin ligand 
expressing 
Melanoma NKI-4 Human Biochemistry 
37:10514 (1998) 
Rolls on PS 
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Cancer Type Line Source Ref Notes 
Small Cell Lung 
Carcinoma 
NCI-H345 Human Biochem. Biophys. 
Res. Commun. 
288:637 (2001) 
 
Breast Cancer ZR-75-30 Human J. Immunol. 2002, 
168, 1690 
 
Small Cell Lung 
Carcinoma 
NCI-H128 
NCI-H146 
Human J. Clin. Invest 
1993,92:804 
attach to platelets via 
PS 
Neuroblastoma hNB5-A2 
SK-N-SH 
Human J. Clin. Invest 
1993,92:804 
attaches to platelets 
via PS 
Tetratocarcinoma CRL 1566 Human J. Clin. Invest 
1993,92:804 
attaches to platelets 
via PS 
Breast Cancer McF-7 
SkBr3 
Human FASEB Journal 
1998;12:1241 
Rolls on PS 
Small Cell Lung 
Carcinoma 
H69 Human FASEB Journal 
1998;12:1243 
Rolls on PS 
Small Cell Lung 
Carcinoma 
N417 
H526 
H249 
DC571 
Human Cancer Res. 52, 5264 reacts with PS Ab 
pre-B 
Lymphoblastic 
lukemia 
NALM-6 Human Cancer Res. 52, 5268 reacts with PS Ab 
Histiocytic 
lymphoma 
U937 Human J. Clin. Invest 
1993,92:804 
 
Gastric 
adenocarcinoma 
Hs746T Human J. Clin. Invest 
1993,92:804 
 
Breast Cancer H3630 
H3396 
Human PNAS 1992, 89:2292 Binds PS  
Colon Carcinoma H3619 Human PNAS 1992, 89:2292 Binds PS 
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Cancer Type Line Source Ref Notes 
Melanoma H3606 
H3620 
Human PNAS 1992, 89:2292 Binds PS 
Colon Carcinoma LS180 
T84 
Colo 205 
Human Can. Res. 1995, 55 
4425 
Binds to all selectins 
Colon Carcinoma Colo 320 Human Can. Res. 1995, 55 
4425 
binding only to PS 
and LS 
Colon Carcinoma H29 Human Can. Res. 1995, 55 
4425 
binding only to ES 
Small Cell Lung 
Carcinoma 
H82 Human Am. J. Physiol (lung) 
15:L918 
binding to PS 
Small Cell Lung 
Carcinoma 
H146 Human Am. J. Physiol (lung) 
15:L918 
binding to PS 
Melanoma A375 Human J. immunol. 2000, 
165:558 
binding to PS 
Colon Carcinoma HT-29M Human J. Clin. Invest 
1993,92:3038 
Rolling and adhesion 
on IL-1 activated 
HUVEC 
Ovarian 
Carcinoma 
OVCAR-3 Human J. Clin. Invest 
1993,92:3038 
Rolling and adhesion 
on IL-1 activated 
HUVEC 
Breast Cancer T-47D Human J. Clin. Invest 
1993,92:3038 
Rolling and adhesion 
on IL-1 activated 
HUVEC 
Melanoma A375M 
A2058 
Human J. Clin. Invest 
1993,92:3038 
no rolling abut 
adhesion on IL-1 
activated HUVEC 
Osteosarcoma MG-63 Human J. Clin. Invest 
1993,92:3038 
no rolling abut 
adhesion on IL-1 
activated HUVEC 
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Cancer Type Line Source Ref Notes 
Prostate MDA PCa 
2b 
PC-3 
PC-3M 
LN4 
PC-3M 
Pro-4 
Human Can. Res. 2004: 64 
5259 
Rolling on ES 
Small Cell 
anaplastic 
carcinoma of 
lung 
QG 90 Human Can. Res. 1995;55 
4162 
Rolling on activated 
HUVEC 
Renal Cancer CCF-RC1 
CCF-RC2 
CCF-RC7 
Human J. Urol. 1996:155 
743 
Adhesion to ICAM-1, 
ES and sLeX 
 
ES  = E-selectin 
PS = P-selectin 
Ab = antibody  
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II.2 Cell lines responsive to TRAIL or TRAIL-R1 and -R2 antibodies 
Cancer Type Line Source Ref Notes 
Colon carcinoma HCT116 
SW480 
Colo205 
human Br J Cancer (2005) 
92: 1430-41 
casp resp to HGS-ETR1 
Hepatocellular 
carcinoma 
SNU-
398 
human Br J Cancer (2005) 
92: 1430-44 
NO casp 3/7 response 
to HGS-ETR11 
Leukemia 
(Chronic 
myeloid 
leukaemia) 
JURL-
MK1 
human Br J Cancer (2005) 
92: 1430-45 
casp resp to HGS-ETR1 
NSCLC (Lung) H2122 
H460 
human Br J Cancer (2005) 
92: 1430-46 
TRAIL-R1 3.1x WT, 
casp resp to HGS-ETR1 
Lymphoma 
(Burkitt’s) 
ST486 human Br J Cancer (2005) 
92: 1430-48 
casp resp to HGS-ETR1 
Melanoma WM793
B 
human Br J Cancer (2005) 
92: 1430-49 
TRAIL-R2 10.2x WT, 
NO casp 3/7 response 
to HGS-ETR1 
Oesophageal 
squamous 
carcinoma 
TTn human Br J Cancer (2005) 
92: 1430-50 
casp resp to HGS-ETR1 
Ovarian clear 
cell carcinoma 
ES2 human Br J Cancer (2005) 
92: 1430-51 
casp resp to HGS-ETR1 
Pancreatic ductal 
carcinoma 
SU.86.8
6 
human Br J Cancer (2005) 
92: 1430-52 
casp resp to HGS-ETR1 
Renal cell 
carcinoma  
A498 human Br J Cancer (2005) 
92: 1430-53 
TRAIL-R1 2.7x WT, 
casp resp to HGS-ETR1 
Uterine 
endometrlial 
carcinoma 
RL95-2 human Br J Cancer (2005) 
92: 1430-54 
casp resp to HGS-ETR1 
Lung Carcinoma SK-
MES-1 
human J. Mol. Biol. (2006) 
361, 522–536 
express DR5 
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Cancer Type Line Source Ref Notes 
NSCLC H2122 
H460 
Human www.hgsi.com in vitro: Responds to 
agonist ab to 
TRAILR2+++, 
expresses TRAILR2++,  
in vivo: reduced tumor 
size++ 
Colon HCT-
116 
Colo205 
human www.hgsi.com in vitro: Responds to 
agonist ab to 
TRAILR2+++, 
expresses TRAILR2++,                 
in vivo: reduced tumor 
size+ 
Ovarian A2780 
SKOV3 
human www.hgsi.com in vitro: Responds to 
agonist ab to 
TRAILR2+++, 
expresses TRAILR2 
Glioma U87   in vivo: reduced tumor 
size+ 
Lymphoma 
Gastric 
Carcinoma 
Cervical 
Carcinoma 
Melanoma 
Liver, 
Adenocarcinoma 
Sarcoma 
Uterine Tumor 
Thyroid 
Carcinoma 
Mesothelioma 
Myeloma 
 human 16th EORTC-NCI-
AACR, 2004 
expresses TRAILR1++ 
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Cancer Type Line Source Ref Notes 
Bladder 
Carcinoma 
Squamous Cell 
Carcinoma 
 human 16th EORTC-NCI-
AACR, 2004 
expresses TRAILR1++ 
 
Casp – caspase 
WT – wild type 
HGS-ETR1 or 2 – Humanized monoclonal antibody against TRAIL R1 and R2 
respectively developed by Human Genomic Sciences 
+, ++, +++, ++++ - represents response or expression of surface protein with ‘+’ being 
lowest. 
